The	O
MHC	B-protein
class	I-protein
II	I-protein
transactivator	I-protein
(	O
CIITA	B-protein
)	O
requires	O
conserved	O
leucine	B-protein
charged	I-protein
domains	I-protein
for	O
interactions	O
with	O
the	O
conserved	O
W	B-DNA
box	I-DNA
promoter	I-DNA
element	I-DNA
.	O

The	O
class	B-protein
II	I-protein
transactivator	I-protein
CIITA	B-protein
is	O
required	O
for	O
transcriptional	O
activation	O
of	O
the	O
major	B-DNA
histocompatibility	I-DNA
complex	I-DNA
(	I-DNA
MHC	I-DNA
)	I-DNA
class	I-DNA
II	I-DNA
genes	I-DNA
.	O

Aside	O
from	O
an	O
N-terminal	B-DNA
acidic	I-DNA
transcriptional	I-DNA
activation	I-DNA
domain	I-DNA
,	O
little	O
is	O
known	O
about	O
how	O
this	O
factor	O
functions	O
.	O

Extensive	O
mutagenesis	O
of	O
CIITA	B-protein
was	O
undertaken	O
to	O
identify	O
structural	O
motifs	O
required	O
for	O
function	O
.	O

The	O
ability	O
of	O
mutants	O
to	O
activate	O
a	O
reporter	O
gene	O
under	O
the	O
control	O
of	O
MHC	B-protein
class	I-protein
II	I-protein
conserved	O
W-X-Y	B-DNA
or	I-DNA
X-Y	I-DNA
regulatory	I-DNA
elements	I-DNA
was	O
determined	O
.	O

Two	O
mutants	O
displayed	O
differential	O
activity	O
between	O
the	O
two	O
promoters	B-DNA
,	O
activating	O
transcription	O
with	O
the	O
W-X-Y	B-DNA
but	I-DNA
not	I-DNA
the	I-DNA
X-Y	I-DNA
elements	I-DNA
.	O

All	O
mutants	O
were	O
tested	O
for	O
their	O
ability	O
to	O
interfere	O
with	O
wild-type	O
CIITA	B-protein
activity	O
.	O

Five	O
CIITA	B-DNA
mutant	I-DNA
constructions	I-DNA
were	O
able	O
to	O
down-regulate	O
wild-type	O
CIITA	B-protein
activity	O
.	O

Three	O
of	O
these	O
mutants	O
contained	O
targeted	O
disruptions	O
of	O
potential	O
functional	O
motifs	O
:	O
the	O
acidic	B-protein
activation	I-protein
domain	I-protein
,	O
a	O
putative	O
GTP-binding	B-protein
motif	I-protein
and	O
two	O
leucine	B-protein
charged	I-protein
domains	I-protein
(	O
LCD	B-protein
motifs	I-protein
)	O
.	O

The	O
other	O
two	O
contained	O
mutations	O
in	O
regions	O
that	O
do	O
not	O
have	O
homology	O
to	O
described	O
proteins	O
.	O

The	O
characterization	O
of	O
CIITA	B-protein
mutants	I-protein
that	O
are	O
able	O
to	O
discriminate	O
between	O
promoters	O
with	O
or	O
without	O
the	O
W	B-DNA
box	I-DNA
strongly	O
suggests	O
that	O
CIITA	B-protein
requires	O
such	O
interactions	O
for	O
function	O
.	O

The	O
identification	O
of	O
LCD	B-protein
motifs	I-protein
required	O
for	O
CIITA	B-protein
function	O
brings	O
to	O
light	O
a	O
previously	O
undefined	O
role	O
of	O
these	O
motifs	O
in	O
CIITA	B-protein
function	O
.	O

4128-4136	NULL
-	NULL
Nucleic	NULL
Acids	NULL
Research	NULL
,	NULL
1998	NULL
,	NULL
Vol	NULL
.	NULL

26	NULL
,	NULL
No	NULL
.	NULL

18	NULL
©	NULL
1998	NULL
Oxford	NULL
University	NULL
Press	NULL
The	NULL
MHC	NULL
class	NULL
II	NULL
transactivator	NULL
(	NULL
CIITA	NULL
)	NULL
requires	NULL
conserved	NULL
leucine	NULL
charged	NULL
domains	NULL
for	NULL
interactions	NULL
with	NULL
the	NULL
conserved	NULL
W	NULL
box	NULL
promoter	NULL
element	NULL
Jeffrey	NULL
A	NULL
.	NULL

Brown	NULL
,	NULL
Edward	NULL
M.	NULL
Rogers	NULL
and	NULL
Jeremy	NULL
M.	NULL
Boss*	NULL
Department	NULL
of	NULL
Microbiology	NULL
and	NULL
Immunology	NULL
,	NULL
Emory	NULL
University	NULL
School	NULL
of	NULL
Medicine	NULL
,	NULL
Atlanta	NULL
,	NULL
GA	NULL
30322	NULL
,	NULL
USA	NULL
Received	NULL
June	NULL
17	NULL
,	NULL
1998	NULL
;	NULL
Accepted	NULL
July	NULL
26	NULL
,	NULL
1998	NULL
ABSTRACT	NULL
The	NULL
class	NULL
II	NULL
transactivator	NULL
CIITA	NULL
is	NULL
required	NULL
for	NULL
transcriptional	NULL
activation	NULL
of	NULL
the	NULL
major	NULL
histocompatibility	NULL
complex	NULL
(	NULL
MHC	NULL
)	NULL
class	NULL
II	NULL
genes	NULL
.	NULL

Aside	NULL
from	NULL
an	NULL
N-terminal	NULL
acidic	NULL
transcriptional	NULL
activation	NULL
domain	NULL
,	NULL
little	NULL
is	NULL
known	NULL
about	NULL
how	NULL
this	NULL
factor	NULL
functions	NULL
.	NULL

Extensive	NULL
mutagenesis	NULL
of	NULL
CIITA	NULL
was	NULL
undertaken	NULL
to	NULL
identify	NULL
structural	NULL
motifs	NULL
required	NULL
for	NULL
function	NULL
.	NULL

The	NULL
ability	NULL
of	NULL
mutants	NULL
to	NULL
activate	NULL
a	NULL
reporter	NULL
gene	NULL
under	NULL
the	NULL
control	NULL
of	NULL
MHC	NULL
class	NULL
II	NULL
conserved	NULL
W-X-Y	NULL
or	NULL
X-Y	NULL
regulatory	NULL
elements	NULL
was	NULL
determined	NULL
.	NULL

Two	NULL
mutants	NULL
displayed	NULL
differential	NULL
activity	NULL
between	NULL
the	NULL
two	NULL
promoters	NULL
,	NULL
activating	NULL
transcription	NULL
with	NULL
the	NULL
W-X-Y	NULL
but	NULL
not	NULL
the	NULL
X-Y	NULL
elements	NULL
.	NULL

All	NULL
mutants	NULL
were	NULL
tested	NULL
for	NULL
their	NULL
ability	NULL
to	NULL
interfere	NULL
with	NULL
wild-type	NULL
CIITA	NULL
activity	NULL
.	NULL

Five	NULL
CIITA	NULL
mutant	NULL
constructions	NULL
were	NULL
able	NULL
to	NULL
down-regulate	NULL
wild-type	NULL
CIITA	NULL
activity	NULL
.	NULL

Three	NULL
of	NULL
these	NULL
mutants	NULL
contained	NULL
targeted	NULL
disruptions	NULL
of	NULL
potential	NULL
functional	NULL
motifs	NULL
:	NULL
the	NULL
acidic	NULL
activation	NULL
domain	NULL
,	NULL
a	NULL
putative	NULL
GTP-binding	NULL
motif	NULL
and	NULL
two	NULL
leucine	NULL
charged	NULL
domains	NULL
(	NULL
LCD	NULL
motifs	NULL
)	NULL
.	NULL

The	NULL
other	NULL
two	NULL
contained	NULL
mutations	NULL
in	NULL
regions	NULL
that	NULL
do	NULL
not	NULL
have	NULL
homology	NULL
to	NULL
described	NULL
proteins	NULL
.	NULL

The	NULL
characterization	NULL
of	NULL
CIITA	NULL
mutants	NULL
that	NULL
are	NULL
able	NULL
to	NULL
discriminate	NULL
between	NULL
promoters	NULL
with	NULL
or	NULL
without	NULL
the	NULL
W	NULL
box	NULL
strongly	NULL
suggests	NULL
that	NULL
CIITA	NULL
requires	NULL
such	NULL
interactions	NULL
for	NULL
function	NULL
.	NULL

The	NULL
identification	NULL
of	NULL
LCD	NULL
motifs	NULL
required	NULL
for	NULL
CIITA	NULL
function	NULL
brings	NULL
to	NULL
light	NULL
a	NULL
previously	NULL
undefined	NULL
role	NULL
of	NULL
these	NULL
motifs	NULL
in	NULL
CIITA	NULL
function	NULL
.	NULL

INTRODUCTION	NULL
Major	NULL
histocompatibility	NULL
complex	NULL
(	NULL
MHC	NULL
)	NULL
class	NULL
II	NULL
genes	NULL
encode	NULL
integral	NULL
components	NULL
of	NULL
the	NULL
immune	NULL
response	NULL
.	NULL

The	NULL
three	NULL
human	NULL
class	NULL
II	NULL
isotypes	NULL
,	NULL
DR	NULL
,	NULL
DQ	NULL
and	NULL
DP	NULL
,	NULL
each	NULL
consisting	NULL
of	NULL
an	NULL
O/B	NULL
heterodimer	NULL
,	NULL
present	NULL
processed	NULL
extracellular	NULL
antigenic	NULL
peptides	NULL
to	NULL
helper	NULL
T	NULL
cells	NULL
(	NULL
1	NULL
)	NULL
.	NULL

Class	NULL
II	NULL
genes	NULL
are	NULL
coordinately	NULL
expressed	NULL
in	NULL
B	NULL
cells	NULL
,	NULL
macrophages	NULL
,	NULL
dendritic	NULL
cells	NULL
and	NULL
thymic	NULL
epithelium	NULL
.	NULL

However	NULL
,	NULL
their	NULL
expression	NULL
can	NULL
be	NULL
induced	NULL
in	NULL
a	NULL
number	NULL
of	NULL
cell	NULL
types	NULL
by	NULL
treatment	NULL
with	NULL
interferon-y	NULL
(	NULL
IFN-y	NULL
)	NULL
(	NULL
2-5	NULL
)	NULL
.	NULL

The	NULL
temporal	NULL
and	NULL
spatial	NULL
regulation	NULL
of	NULL
class	NULL
II	NULL
gene	NULL
expression	NULL
is	NULL
vital	NULL
to	NULL
the	NULL
maintenance	NULL
of	NULL
a	NULL
functional	NULL
immune	NULL
system	NULL
.	NULL

Clues	NULL
to	NULL
the	NULL
mechanism	NULL
of	NULL
class	NULL
II	NULL
gene	NULL
regulation	NULL
have	NULL
come	NULL
from	NULL
analyses	NULL
of	NULL
cell	NULL
lines	NULL
from	NULL
patients	NULL
exhibiting	NULL
the	NULL
bare	NULL
lymphocyte	NULL
syndrome	NULL
(	NULL
BLS	NULL
)	NULL
,	NULL
an	NULL
inherited	NULL
immunodeficiency	NULL
(	NULL
reviewed	NULL
in	NULL
6,7	NULL
)	NULL
.	NULL

BLS	NULL
patients	NULL
lack	NULL
all	NULL
class	NULL
II	NULL
expression	NULL
,	NULL
resulting	NULL
in	NULL
an	NULL
inability	NULL
to	NULL
mount	NULL
an	NULL
immune	NULL
response	NULL
to	NULL
soluble	NULL
antigens	NULL
(	NULL
8,9	NULL
)	NULL
.	NULL

Four	NULL
clear	NULL
BLS	NULL
complementation	NULL
groups	NULL
have	NULL
been	NULL
defined	NULL
,	NULL
each	NULL
deficient	NULL
in	NULL
a	NULL
necessary	NULL
trans-acting	NULL
factor	NULL
(	NULL
6,10,11	NULL
)	NULL
.	NULL

The	NULL
promoters	NULL
of	NULL
class	NULL
II	NULL
genes	NULL
contain	NULL
three	NULL
conserved	NULL
regulatory	NULL
elements	NULL
,	NULL
termed	NULL
the	NULL
W	NULL
,	NULL
X	NULL
and	NULL
Y	NULL
boxes	NULL
(	NULL
3,12	NULL
)	NULL
.	NULL

The	NULL
W	NULL
box	NULL
is	NULL
the	NULL
most	NULL
upstream	NULL
of	NULL
the	NULL
elements	NULL
and	NULL
is	NULL
required	NULL
for	NULL
IFN-y-induced	NULL
and	NULL
maximal	NULL
B	NULL
cell	NULL
expression	NULL
of	NULL
class	NULL
II	NULL
genes	NULL
(	NULL
13-17	NULL
)	NULL
.	NULL

While	NULL
the	NULL
role	NULL
of	NULL
the	NULL
W	NULL
box	NULL
in	NULL
IFN-y	NULL
induction	NULL
has	NULL
been	NULL
well	NULL
documented	NULL
(	NULL
16,17	NULL
)	NULL
,	NULL
the	NULL
mechanism	NULL
for	NULL
this	NULL
requirement	NULL
has	NULL
remained	NULL
elusive	NULL
,	NULL
presumably	NULL
because	NULL
the	NULL
factors	NULL
that	NULL
bind	NULL
to	NULL
the	NULL
W	NULL
box	NULL
have	NULL
not	NULL
been	NULL
well	NULL
characterized	NULL
.	NULL

A	NULL
recent	NULL
report	NULL
suggested	NULL
that	NULL
RFX	NULL
,	NULL
a	NULL
factor	NULL
that	NULL
binds	NULL
to	NULL
the	NULL
X1	NULL
box	NULL
(	NULL
see	NULL
below	NULL
)	NULL
,	NULL
binds	NULL
weakly	NULL
to	NULL
the	NULL
smaller	NULL
S	NULL
box	NULL
region	NULL
within	NULL
the	NULL
W	NULL
box	NULL
(	NULL
18	NULL
)	NULL
.	NULL

The	NULL
X	NULL
box	NULL
,	NULL
both	NULL
necessary	NULL
and	NULL
sufficient	NULL
for	NULL
class	NULL
II	NULL
expression	NULL
in	NULL
B	NULL
cells	NULL
(	NULL
14,15,19	NULL
)	NULL
,	NULL
has	NULL
been	NULL
biochemically	NULL
and	NULL
genetically	NULL
subdivided	NULL
into	NULL
the	NULL
X1	NULL
and	NULL
X2	NULL
boxes	NULL
(	NULL
13,14	NULL
)	NULL
.	NULL

RFX	NULL
,	NULL
a	NULL
multimeric	NULL
protein	NULL
complex	NULL
consisting	NULL
of	NULL
75	NULL
,	NULL
41	NULL
and	NULL
36	NULL
kDa	NULL
subunits	NULL
,	NULL
binds	NULL
to	NULL
the	NULL
X1	NULL
box	NULL
(	NULL
20,21	NULL
)	NULL
.	NULL

RFX	NULL
activity	NULL
is	NULL
deficient	NULL
in	NULL
three	NULL
of	NULL
the	NULL
BLS	NULL
complementation	NULL
groups	NULL
(	NULL
B	NULL
,	NULL
C	NULL
and	NULL
D	NULL
)	NULL
(	NULL
13,21-25	NULL
)	NULL
.	NULL

The	NULL
factor	NULL
X2BP	NULL
has	NULL
been	NULL
shown	NULL
to	NULL
bind	NULL
the	NULL
X2	NULL
box	NULL
and	NULL
has	NULL
been	NULL
described	NULL
(	NULL
26-29	NULL
)	NULL
.	NULL

The	NULL
Y	NULL
box	NULL
,	NULL
an	NULL
inverted	NULL
CCAAT	NULL
motif	NULL
,	NULL
has	NULL
been	NULL
shown	NULL
to	NULL
bind	NULL
the	NULL
minor	NULL
groove	NULL
DNA-binding	NULL
protein	NULL
NF-Y	NULL
(	NULL
30	NULL
)	NULL
.	NULL

The	NULL
X	NULL
and	NULL
Y	NULL
box	NULL
factors	NULL
form	NULL
synergistic	NULL
complexes	NULL
on	NULL
all	NULL
class	NULL
II	NULL
promoters	NULL
(	NULL
28,31	NULL
)	NULL
and	NULL
therefore	NULL
appear	NULL
to	NULL
coordinate	NULL
the	NULL
regulation	NULL
of	NULL
all	NULL
class	NULL
II	NULL
genes	NULL
.	NULL

The	NULL
class	NULL
II	NULL
transactivator	NULL
CIITA	NULL
appears	NULL
to	NULL
function	NULL
as	NULL
a	NULL
master	NULL
regulatory	NULL
switch	NULL
for	NULL
class	NULL
II	NULL
expression	NULL
.	NULL

CIITA	NULL
is	NULL
mutated	NULL
in	NULL
BLS	NULL
complementation	NULL
group	NULL
A	NULL
(	NULL
32	NULL
)	NULL
.	NULL

Expression	NULL
of	NULL
CITA	NULL
correlates	NULL
exactly	NULL
with	NULL
class	NULL
II	NULL
expression	NULL
in	NULL
both	NULL
antigen-presenting	NULL
cells	NULL
and	NULL
cells	NULL
induced	NULL
to	NULL
express	NULL
class	NULL
II	NULL
genes	NULL
by	NULL
IFN-y	NULL
(	NULL
32	NULL
)	NULL
.	NULL

Moreover	NULL
,	NULL
class	NULL
II	NULL
negative	NULL
cells	NULL
transfected	NULL
with	NULL
CITA	NULL
express	NULL
class	NULL
II	NULL
genes	NULL
(	NULL
33-37	NULL
)	NULL
,	NULL
suggesting	NULL
that	NULL
CITA	NULL
expression	NULL
is	NULL
a	NULL
limiting	NULL
component	NULL
of	NULL
class	NULL
II	NULL
gene	NULL
regulation	NULL
.	NULL

CIITA	NULL
does	NULL
not	NULL
appear	NULL
to	NULL
bind	NULL
DNA	NULL
.	NULL

Analysis	NULL
of	NULL
the	NULL
1130	NULL
residue	NULL
primary	NULL
amino	NULL
acid	NULL
sequence	NULL
of	NULL
CIHITA	NULL
(	NULL
32	NULL
)	NULL
revealed	NULL
an	NULL
acidic	NULL
region	NULL
,	NULL
a	NULL
proline/serine/threonine-rich	NULL
(	NULL
P/S/T	NULL
)	NULL
region	NULL
,	NULL
a	NULL
consensus	NULL
GTP-binding	NULL
motif	NULL
(	NULL
38	NULL
)	NULL
,	NULL
a	NULL
leucine-rich	NULL
region	NULL
and	NULL
four	NULL
leucine	NULL
and	NULL
charged	NULL
residue-rich	NULL
domains	NULL
(	NULL
LCD	NULL
)	NULL
.	NULL

The	NULL
acidic	NULL
domain	NULL
has	NULL
*To	NULL
whom	NULL
correspondence	NULL
should	NULL
be	NULL
addressed	NULL
.	NULL

Tel	NULL
:	NULL
+1	NULL
404	NULL
727	NULL
5973	NULL
;	NULL
Fax	NULL
:	NULL
+1	NULL
404	NULL
727	NULL
1719	NULL
;	NULL
Email	NULL
:	NULL
boss	NULL
@	NULL
microbio.emory.edu	NULL
Table	NULL
1	NULL
.	NULL

Primers	NULL
used	NULL
for	NULL
construction	NULL
of	NULL
the	NULL
CIITA	NULL
mutants	NULL
Nucleic	NULL
Acids	NULL
Research	NULL
,	NULL
1998	NULL
,	NULL
Vol	NULL
.	NULL

26	NULL
,	NULL
No	NULL
.	NULL

18	NULL
-	NULL
4129	NULL
CONSTRUCT	NULL
(	NULL
bp	NULL
deleted	NULL
)	NULL
5°	NULL
Primer	NULL
(	NULL
bp	NULL
)	NULL
OL-PCR	NULL
Primer®	NULL
3	NULL
``	NULL
Primer	NULL
(	NULL
bp	NULL
)	NULL
A1	NULL
(	NULL
1099-1129	NULL
)	NULL
A2	NULL
(	NULL
1217-1246	NULL
)	NULL
A3	NULL
(	NULL
1376-1408	NULL
)	NULL
A4	NULL
(	NULL
1436-1465	NULL
)	NULL
A5	NULL
(	NULL
1499-1528	NULL
)	NULL
A6	NULL
(	NULL
1862-1894	NULL
)	NULL
A7	NULL
(	NULL
2165-2194	NULL
)	NULL
AB	NULL
(	NULL
2486-2530	NULL
)	NULL
A9	NULL
(	NULL
2771-2806	NULL
)	NULL
A10	NULL
(	NULL
3047-3076	NULL
)	NULL
A11	NULL
(	NULL
3224-3262	NULL
)	NULL
A12	NULL
(	NULL
3458-3487	NULL
)	NULL
(	NULL
799	NULL
)	NULL
5-GTTTGTCCCCACCATCTCCAC	NULL
(	NULL
799	NULL
)	NULL
(	NULL
799	NULL
)	NULL
(	NULL
799	NULL
)	NULL
(	NULL
799	NULL
)	NULL
(	NULL
799	NULL
)	NULL
(	NULL
799	NULL
)	NULL
(	NULL
799	NULL
)	NULL
(	NULL
799	NULL
)	NULL
(	NULL
2288	NULL
)	NULL
5-AGTGGCGAAATCAAGGACAAGG	NULL
(	NULL
2288	NULL
)	NULL
(	NULL
2288	NULL
)	NULL
5-GCTGGAGAGGTCTCC/GAGCAGTTCTACCG	NULL
5-GGTGGATCTGGTGCA/GCTGGAGCGGGAACTG	NULL
5-ATTGCTGTGCTGGGC/GCAGTGAGCCGG	NULL
@	NULL
Cc	NULL
§-GCCTGGGCTTGTGGC/GTCCCCTGCCaTTGC	NULL
5-AACCGTCCGGGGGAT/CTGGGCCCACAGCCA	NULL
5-	NULL
@	NULL
TGATGCGCTACTTT/CCCCTGACGCTCCTCCGG	NULL
5-CAGTTCCCATCCGCA/TTAGTCCAACACCCA	NULL
5-CAGAAGGTGCTTGCG/CTGCTTGAGCTGCTa	NULL
5-TGTGTCACCCGTTTCTCCCTGCGGCAGCAT	NULL
5-TTCCCCAAACTGGTG/CATCTGGACCTGGAT	NULL
5-GCCTACAAACTCGCC/AGCTTGTACAATAAC	NULL
(	NULL
2041	NULL
)	NULL
5-GACATAGAGTCCCGTGAGCG	NULL
(	NULL
2041	NULL
)	NULL
(	NULL
2408	NULL
)	NULL
5-TGGAAGATCAGCCCAGCCAGAAAGC	NULL
(	NULL
2041	NULL
)	NULL
(	NULL
2406	NULL
)	NULL
(	NULL
2406	NULL
)	NULL
(	NULL
2406	NULL
)	NULL
(	NULL
3118	NULL
)	NULL
5-GTCCCCGaATCTraTTcTcactc	NULL
(	NULL
3118	NULL
)	NULL
(	NULL
3566	NULL
)	NULL
5-CAAGGTCCAGCGTG	NULL
@	NULL
TTAGTaTCcTcaq	NULL
(	NULL
3566	NULL
)	NULL
*	NULL
(	NULL
pSVK3	NULL
)	NULL
)	NULL
5-TACGCCCCGCCCTaCcactc	NULL
161-1130	NULL
(	NULL
a.a.	NULL
1-160	NULL
)	NULL
mutL1	NULL
t	NULL
(	NULL
599	NULL
)	NULL
5-GCTCTAGACCATGGAGCCCCCCACTGTG	NULL
(	NULL
1447	NULL
)	NULL
5	NULL
'	NULL
-	NULL
GCTTGTGGCCGGCTTCCCCaGT	NULL
115-GCCTATGGCGCACAGGATGCTGC	NULL
@	NULL
TTCTCCCTG	NULL
mutL2	NULL
(	NULL
1447	NULL
)	NULL
115-CCCTGCTCCGETCGGGGGGCAGCAGCCGGCCTT	NULL
(	NULL
2406	NULL
)	NULL
A13	NULL
(	NULL
104	NULL
)	NULL
5	NULL
'	NULL
-	NULL
GATTCCTACACAATGCGTTGCCTGGCTC	NULL
-	NULL
|5-GCAGAAGTTGGGCAGGCTGAGCCCCCCAGT	NULL
(	NULL
1537	NULL
)	NULL
mutCDK	NULL
(	NULL
104	NULL
)	NULL
t	NULL
}	NULL
5-GGCCTCCCAACAGCTGCGGACG	NULL
@	NULL
CCCCAGGCTCCACC	NULL
|	NULL
(	NULL
1537	NULL
)	NULL
(	NULL
1537	NULL
)	NULL
5°	NULL
-	NULL
GGGCCCAGGGAGAAGAGCAGAT	NULL
(	NULL
2406	NULL
)	NULL
All	NULL
primer	NULL
sequences	NULL
are	NULL
given	NULL
in	NULL
the	NULL
5/-	NULL
>	NULL
3	NULL
'	NULL
direction	NULL
with	NULL
the	NULL
position	NULL
of	NULL
the	NULL
5	NULL
``	NULL
base	NULL
indicated	NULL
.	NULL

*For	NULL
complementary	NULL
OL-PCR	NULL
primers	NULL
,	NULL
the	NULL
sequence	NULL
is	NULL
given	NULL
for	NULL
the	NULL
coding	NULL
strand	NULL
of	NULL
CHTA	NULL
.	NULL

**Primer	NULL
pSVK3	NULL
'	NULL
anneals	NULL
to	NULL
the	NULL
MCS	NULL
of	NULL
pSVK-Flag-CIITA	NULL
,	NULL
immediately	NULL
downstream	NULL
of	NULL
CITA	NULL
.	NULL

tThe	NULL
primer	NULL
adds	NULL
a	NULL
Xbal	NULL
site	NULL
and	NULL
Koxak	NULL
consensus	NULL
translation	NULL
start	NULL
site	NULL
such	NULL
that	NULL
the	NULL
protein	NULL
begins	NULL
at	NULL
wild-type	NULL
residue	NULL
161	NULL
.	NULL

TTSequence	NULL
changes	NULL
that	NULL
lead	NULL
to	NULL
alanine	NULL
substitutions	NULL
are	NULL
underlined	NULL
.	NULL

been	NULL
shown	NULL
to	NULL
act	NULL
as	NULL
a	NULL
transcriptional	NULL
activation	NULL
domain	NULL
in	NULL
both	NULL
mammalian	NULL
and	NULL
yeast	NULL
systems	NULL
(	NULL
39,40	NULL
)	NULL
.	NULL

Mahanta	NULL
et	NULL
al	NULL
.	NULL

(	NULL
41	NULL
)	NULL
recently	NULL
showed	NULL
that	NULL
this	NULL
transcriptional	NULL
activation	NULL
domain	NULL
functions	NULL
similarly	NULL
to	NULL
that	NULL
of	NULL
VP16	NULL
by	NULL
interacting	NULL
with	NULL
the	NULL
TATA-binding	NULL
protein	NULL
TBP	NULL
and	NULL
several	NULL
TBP-associated	NULL
factors	NULL
.	NULL

No	NULL
function	NULL
has	NULL
been	NULL
ascribed	NULL
to	NULL
the	NULL
P/S/T	NULL
region	NULL
,	NULL
but	NULL
it	NULL
has	NULL
been	NULL
shown	NULL
that	NULL
it	NULL
is	NULL
required	NULL
for	NULL
CHTA	NULL
activity	NULL
(	NULL
42	NULL
)	NULL
.	NULL

The	NULL
mechanism	NULL
for	NULL
CHITA	NULL
action	NULL
is	NULL
poorly	NULL
understood	NULL
;	NULL
recent	NULL
studies	NULL
have	NULL
suggested	NULL
that	NULL
CIITA	NULL
functions	NULL
as	NULL
a	NULL
coactivator	NULL
by	NULL
interacting	NULL
with	NULL
X	NULL
box	NULL
DNA-bound	NULL
transcription	NULL
factors	NULL
and	NULL
activating	NULL
transcription	NULL
through	NULL
its	NULL
activation	NULL
domain	NULL
(	NULL
39,40	NULL
)	NULL
.	NULL

To	NULL
further	NULL
investigate	NULL
the	NULL
mechanism	NULL
of	NULL
CITA	NULL
function	NULL
,	NULL
a	NULL
series	NULL
of	NULL
internal	NULL
deletion	NULL
and	NULL
substitution	NULL
mutants	NULL
was	NULL
created	NULL
.	NULL

The	NULL
mutants	NULL
were	NULL
tested	NULL
for	NULL
their	NULL
ability	NULL
to	NULL
activate	NULL
class	NULL
II-specific	NULL
reporter	NULL
gene	NULL
constructs	NULL
and	NULL
for	NULL
their	NULL
ability	NULL
to	NULL
interfere	NULL
with	NULL
the	NULL
function	NULL
of	NULL
wild-type	NULL
CIITA	NULL
.	NULL

It	NULL
was	NULL
found	NULL
that	NULL
deletions	NULL
spanning	NULL
the	NULL
C-terminal	NULL
two	NULL
thirds	NULL
of	NULL
the	NULL
protein	NULL
abrogated	NULL
CIITA	NULL
function	NULL
.	NULL

Two	NULL
mutants	NULL
were	NULL
found	NULL
to	NULL
discriminate	NULL
between	NULL
a	NULL
W-X-Y-driven	NULL
reporter	NULL
and	NULL
an	NULL
X-Y	NULL
reporter	NULL
,	NULL
suggesting	NULL
direct	NULL
interaction	NULL
with	NULL
the	NULL
class	NULL
II-specific	NULL
transcription	NULL
factor	NULL
(	NULL
s	NULL
)	NULL
bound	NULL
at	NULL
the	NULL
W	NULL
box	NULL
;	NULL
both	NULL
of	NULL
these	NULL
mutants	NULL
contained	NULL
disruptions	NULL
of	NULL
conserved	NULL
LCD	NULL
motifs	NULL
,	NULL
highlighting	NULL
the	NULL
potential	NULL
involvement	NULL
of	NULL
these	NULL
motifs	NULL
in	NULL
CITA	NULL
function	NULL
.	NULL

Numerous	NULL
mutations	NULL
resulted	NULL
in	NULL
proteins	NULL
that	NULL
were	NULL
able	NULL
to	NULL
interfere	NULL
with	NULL
the	NULL
function	NULL
of	NULL
wild-type	NULL
CIITA	NULL
,	NULL
indicating	NULL
that	NULL
in	NULL
addition	NULL
to	NULL
the	NULL
activation	NULL
domain	NULL
,	NULL
CHITA	NULL
requires	NULL
additional	NULL
regions	NULL
for	NULL
activity	NULL
.	NULL

Thus	NULL
,	NULL
the	NULL
analysis	NULL
of	NULL
these	NULL
mutants	NULL
brings	NULL
to	NULL
light	NULL
additional	NULL
functions	NULL
of	NULL
CIITA	NULL
,	NULL
including	NULL
the	NULL
potential	NULL
for	NULL
interactions	NULL
with	NULL
the	NULL
W	NULL
box	NULL
promoter	NULL
element	NULL
and	NULL
a	NULL
functional	NULL
requirement	NULL
for	NULL
LCD	NULL
motifs	NULL
and	NULL
neighboring	NULL
residues	NULL
.	NULL

MATERIALS	NULL
AND	NULL
METHODS	NULL
Cell	NULL
culture	NULL
Raji	NULL
is	NULL
a	NULL
B	NULL
cell	NULL
line	NULL
derived	NULL
from	NULL
a	NULL
patient	NULL
with	NULL
Burkitt	NULL
's	NULL
lymphoma	NULL
(	NULL
43	NULL
)	NULL
.	NULL

RJ2.2.5	NULL
is	NULL
an	NULL
MHC	NULL
class	NULL
II	NULL
negative	NULL
derivative	NULL
of	NULL
Raji	NULL
and	NULL
was	NULL
provided	NULL
by	NULL
Dr	NULL
R.	NULL
Acolla	NULL
(	NULL
44	NULL
)	NULL
.	NULL

Both	NULL
cell	NULL
lines	NULL
were	NULL
grown	NULL
in	NULL
RPMI	NULL
1640	NULL
medium	NULL
(	NULL
Gibco	NULL
BRL	NULL
,	NULL
Grand	NULL
Island	NULL
,	NULL
NY	NULL
)	NULL
,	NULL
supplemented	NULL
with	NULL
5	NULL
%	NULL
fetal	NULL
bovine	NULL
serum	NULL
(	NULL
Intergen	NULL
Inc.	NULL
,	NULL
Purchase	NULL
,	NULL
NY	NULL
)	NULL
,	NULL
5	NULL
%	NULL
calf	NULL
serum	NULL
(	NULL
Hyclone	NULL
Inc.	NULL
,	NULL
Logan	NULL
,	NULL
UT	NULL
)	NULL
,	NULL
2	NULL
mM	NULL
L-glutamine	NULL
(	NULL
Gibco	NULL
BRL	NULL
)	NULL
,	NULL
100	NULL
U/ml	NULL
penicillin	NULL
and	NULL
100	NULL
U/ml	NULL
streptomycin	NULL
(	NULL
Gibco	NULL
BRL	NULL
)	NULL
.	NULL

CIITA	NULL
plasmids	NULL
Wild-type	NULL
CITA	NULL
was	NULL
cloned	NULL
into	NULL
the	NULL
eukaryotic	NULL
expression	NULL
vector	NULL
pSVK3	NULL
(	NULL
Invitrogen	NULL
Corp.	NULL
,	NULL
Carlsbad	NULL
,	NULL
CA	NULL
)	NULL
,	NULL
with	NULL
an	NULL
N-terminal	NULL
FLAG	NULL
epitope	NULL
tag	NULL
(	NULL
IBI	NULL
,	NULL
Corning	NULL
,	NULL
NY	NULL
)	NULL
,	NULL
which	NULL
was	NULL
used	NULL
as	NULL
the	NULL
base	NULL
vector	NULL
for	NULL
mutagenesis	NULL
.	NULL

Overlap	NULL
PCR	NULL
(	NULL
OL-PCR	NULL
)	NULL
mutagenesis	NULL
was	NULL
used	NULL
to	NULL
design	NULL
the	NULL
internal	NULL
deletion	NULL
and	NULL
amino	NULL
acid	NULL
substitution	NULL
mutants	NULL
.	NULL

Two	NULL
complementary	NULL
overlap	NULL
primers	NULL
containing	NULL
the	NULL
desired	NULL
mutation	NULL
were	NULL
used	NULL
separately	NULL
in	NULL
PCRs	NULL
with	NULL
CHITA-specific	NULL
primers	NULL
5°	NULL
or	NULL
3	NULL
``	NULL
of	NULL
the	NULL
deletion	NULL
(	NULL
Table	NULL
1	NULL
)	NULL
.	NULL

PCR	NULL
products	NULL
were	NULL
mixed	NULL
and	NULL
used	NULL
as	NULL
template	NULL
for	NULL
OL-PCR	NULL
amplification	NULL
using	NULL
the	NULL
CIITA-specific	NULL
primers	NULL
.	NULL

The	NULL
OL-PCR	NULL
product	NULL
was	NULL
cloned	NULL
into	NULL
a	NULL
wild-type	NULL
CIITA	NULL
background	NULL
using	NULL
available	NULL
restriction	NULL
sites	NULL
(	NULL
all	NULL
restriction	NULL
enzymes	NULL
were	NULL
from	NULL
New	NULL
England	NULL
Biolabs	NULL
,	NULL
Beverly	NULL
,	NULL
MA	NULL
)	NULL
.	NULL

Incorporation	NULL
of	NULL
mutations	NULL
was	NULL
monitored	NULL
by	NULL
ablation	NULL
of	NULL
restriction	NULL
sites	NULL
and	NULL
all	NULL
PCR-derived	NULL
sequences	NULL
were	NULL
checked	NULL
by	NULL
DNA	NULL
sequencing	NULL
.	NULL

Zn	NULL
vitro	NULL
transcribed	NULL
and	NULL
translated	NULL
proteins	NULL
were	NULL
prepared	NULL
using	NULL
the	NULL
TnT	NULL
kit	NULL
(	NULL
Promega	NULL
Corp.	NULL
,	NULL
Madison	NULL
,	NULL
WI	NULL
)	NULL
as	NULL
described	NULL
by	NULL
the	NULL
manufacturer	NULL
.	NULL

Transient	NULL
transfections	NULL
and	NULL
CAT	NULL
ELISAs	NULL
CAT	NULL
reporter	NULL
constructs	NULL
pDRW-X-Y	NULL
and	NULL
pDRGX1-X2-Y	NULL
,	NULL
containing	NULL
the	NULL
W-X-Y	NULL
or	NULL
X-Y	NULL
motifs	NULL
5°	NULL
of	NULL
the	NULL
minimal	NULL
DRA	NULL
promoter	NULL
,	NULL
respectively	NULL
,	NULL
were	NULL
used	NULL
(	NULL
13,27	NULL
)	NULL
.	NULL

Co-transfections	NULL
were	NULL
performed	NULL
by	NULL
electroporation	NULL
as	NULL
previously	NULL
described	NULL
(	NULL
27	NULL
)	NULL
.	NULL

For	NULL
RJ2.2.5	NULL
transfections	NULL
,	NULL
cells	NULL
were	NULL
harvested	NULL
70	NULL
h	NULL
post-transfection	NULL
,	NULL
washed	NULL
,	NULL
and	NULL
lysed	NULL
by	NULL
three	NULL
rounds	NULL
of	NULL
freezing	NULL
and	NULL
thawing	NULL
.	NULL

CAT	NULL
expression	NULL
was	NULL
measured	NULL
by	NULL
an	NULL
ELISA	NULL
(	NULL
Boehringer	NULL
Mannheim	NULL
,	NULL
Indianapolis	NULL
,	NULL
IN	NULL
)	NULL
.	NULL

For	NULL
Raji	NULL
transfections	NULL
,	NULL
cells	NULL
were	NULL
harvested	NULL
at	NULL
48	NULL
h	NULL
post-transfection	NULL
,	NULL
a	NULL
time	NULL
point	NULL
determined	NULL
by	NULL
flow	NULL
cytometry	NULL
to	NULL
be	NULL
optimal	NULL
for	NULL
a	NULL
dominant	NULL
negative	NULL
effect	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
,	NULL
washed	NULL
,	NULL
lysed	NULL
,	NULL
and	NULL
assayed	NULL
by	NULL
ELISA	NULL
as	NULL
above	NULL
.	NULL

4130	NULL
Nucleic	NULL
Acids	NULL
Research	NULL
,	NULL
1998	NULL
,	NULL
Vol	NULL
.	NULL

26	NULL
,	NULL
No	NULL
.	NULL

18	NULL
WT	NULL
-	NULL
&	NULL
-u	NULL
ms	NULL
D/E	NULL
PIST	NULL
G1G3	NULL
G4	NULL
L3L4	NULL
LRR	NULL
L1L2	NULL
A1	NULL
(	NULL
329-338	NULL
)	NULL
A	NULL
2	NULL
(	NULL
368-377	NULL
)	NULL
A	NULL
3	NULL
(	NULL
421-431	NULL
)	NULL
mms	NULL
l	NULL
mmm	NULL
...	NULL
.	NULL

A	NULL
4	NULL
(	NULL
441-450	NULL
)	NULL
-me	NULL
o	NULL
,	NULL
o-a-o	NULL
momo	NULL
0	NULL
A	NULL
5	NULL
(	NULL
462-47	NULL
1	NULL
)	NULL
-mm	NULL
W	NULL
P	NULL
A	NULL
6	NULL
(	NULL
583-503	NULL
)	NULL
.more	NULL
as	NULL
o	NULL
n-a	NULL
pm	NULL
AT	NULL
(	NULL
684-693	NULL
)	NULL
-me	NULL
m-o	NULL
--	NULL
r	NULL
/	NULL
pom	NULL
A	NULL
8	NULL
(	NULL
791-805	NULL
)	NULL
A9	NULL
(	NULL
886-897	NULL
)	NULL
A	NULL
10	NULL
(	NULL
978-987	NULL
)	NULL
-me	NULL
n-a	NULL
A	NULL
11	NULL
(	NULL
1037-1049	NULL
)	NULL
a	NULL
-m-s-o	NULL
n	NULL
n	NULL
A	NULL
12	NULL
(	NULL
11154124	NULL
)	NULL
(	NULL
161-1130	NULL
)	NULL
(	NULL
1-160	NULL
)	NULL
rommmmmme	NULL
p	NULL
mmm	NULL
...	NULL
mut	NULL
L1	NULL
L	NULL
(	NULL
465	NULL
,	NULL
468	NULL
,	NULL
469	NULL
)	NULL
A	NULL
a-m-4-s	NULL
a-	NULL
»	NULL
F	NULL
mut	NULL
L2	NULL
L	NULL
(	NULL
525	NULL
,	NULL
528	NULL
,	NULL
529	NULL
)	NULL
A	NULL
~s	NULL
c	NULL
l	NULL
M	NULL
A	NULL
5	NULL
,	NULL
mut	NULL
L2	NULL
(	NULL
462-471	NULL
)	NULL
,	NULL
ee	NULL
uu	NULL
£4525	NULL
.	NULL

528	NULL
,	NULL
529	NULL
)	NULL
,	NULL
V	NULL
ooo	NULL
Figure	NULL
1	NULL
.	NULL

CIITA	NULL
deletion	NULL
mutants	NULL
used	NULL
in	NULL
this	NULL
study	NULL
.	NULL

(	NULL
Top	NULL
)	NULL
Wild-type	NULL
CIITA	NULL
with	NULL
the	NULL
acidic	NULL
activation	NULL
(	NULL
D/E	NULL
)	NULL
,	NULL
P/S/T	NULL
,	NULL
GTP	NULL
consensus	NULL
(	NULL
G1	NULL
,	NULL
G3	NULL
and	NULL
G4	NULL
)	NULL
,	NULL
LCD	NULL
(	NULL
L1-L4	NULL
)	NULL
and	NULL
leucine-rich	NULL
regions	NULL
(	NULL
LRR	NULL
)	NULL
indicated	NULL
.	NULL

(	NULL
Below	NULL
)	NULL
CIITA	NULL
mutants	NULL
created	NULL
for	NULL
this	NULL
study	NULL
.	NULL

Amino	NULL
acid	NULL
residues	NULL
deleted	NULL
or	NULL
changed	NULL
are	NULL
indicated	NULL
in	NULL
parentheses	NULL
,	NULL
with	NULL
a	NULL
schematic	NULL
approximating	NULL
the	NULL
locations	NULL
of	NULL
the	NULL
individual	NULL
mutations	NULL
along	NULL
the	NULL
length	NULL
of	NULL
CIITA	NULL
.	NULL

Internal	NULL
deletion	NULL
mutants	NULL
(	NULL
V	NULL
)	NULL
were	NULL
created	NULL
using	NULL
OL-PCR	NULL
as	NULL
described	NULL
in	NULL
Materials	NULL
and	NULL
Methods	NULL
;	NULL
the	NULL
sequences	NULL
of	NULL
PCR	NULL
primers	NULL
used	NULL
can	NULL
be	NULL
found	NULL
in	NULL
Table	NULL
1	NULL
.	NULL

Asterisks	NULL
(	NULL
*	NULL
)	NULL
indicate	NULL
regions	NULL
containing	NULL
alanine	NULL
substitutions	NULL
.	NULL

Generation	NULL
of	NULL
¢-CIITA	NULL
antisera	NULL
and	NULL
immunoblot	NULL
analysis	NULL
A	NULL
bacterial	NULL
expressed	NULL
maltose-binding	NULL
protein-CIITA	NULL
fusion	NULL
protein	NULL
(	NULL
MBP-CIITA	NULL
)	NULL
was	NULL
used	NULL
to	NULL
generate	NULL
polyclonal	NULL
antiserum	NULL
.	NULL

CHTA-specific	NULL
IgG	NULL
antibodies	NULL
were	NULL
purified	NULL
by	NULL
chromatography	NULL
over	NULL
a	NULL
protein	NULL
A	NULL
column	NULL
as	NULL
described	NULL
by	NULL
the	NULL
manufacturer	NULL
(	NULL
Pharmacia	NULL
Biotech	NULL
,	NULL
Piscataway	NULL
,	NULL
NJ	NULL
)	NULL
.	NULL

Cell	NULL
lysates	NULL
were	NULL
separated	NULL
by	NULL
7.5	NULL
%	NULL
SDS-PAGE	NULL
and	NULL
transferred	NULL
to	NULL
PVDF	NULL
membranes	NULL
as	NULL
described	NULL
(	NULL
45	NULL
)	NULL
.	NULL

Western	NULL
blots	NULL
were	NULL
blocked	NULL
overnight	NULL
in	NULL
10	NULL
%	NULL
non-fat	NULL
dry	NULL
milk	NULL
(	NULL
w/v	NULL
)	NULL
in	NULL
PBS-T	NULL
(	NULL
0.1	NULL
%	NULL
Tween-20	NULL
)	NULL
at	NULL
room	NULL
temperature	NULL
with	NULL
agitation	NULL
.	NULL

Polyclonal	NULL
o-CIITA	NULL
antiserum	NULL
was	NULL
diluted	NULL
1:2000	NULL
in	NULL
block	NULL
solution	NULL
;	NULL
blots	NULL
were	NULL
incubated	NULL
in	NULL
primary	NULL
antibody	NULL
solution	NULL
for	NULL
1	NULL
h	NULL
at	NULL
room	NULL
temperature	NULL
with	NULL
agitation	NULL
.	NULL

Blots	NULL
were	NULL
washed	NULL
in	NULL
PBS-T	NULL
and	NULL
incubated	NULL
for	NULL
1	NULL
h	NULL
in	NULL
secondary	NULL
antibody	NULL
(	NULL
HRP-conjugated	NULL
anti-rabbit	NULL
IgG	NULL
;	NULL
Sigma	NULL
,	NULL
St	NULL
Louis	NULL
,	NULL
MO	NULL
)	NULL
diluted	NULL
1:3000	NULL
in	NULL
block	NULL
solution	NULL
.	NULL

Blots	NULL
were	NULL
washed	NULL
as	NULL
above	NULL
and	NULL
developed	NULL
using	NULL
enhanced	NULL
chemiluminescence	NULL
(	NULL
ECL	NULL
system	NULL
;	NULL
Amersham	NULL
Life	NULL
Science	NULL
,	NULL
Arlington	NULL
Heights	NULL
,	NULL
IL	NULL
)	NULL
.	NULL

RESULTS	NULL
CIITA	NULL
deletion	NULL
mutants	NULL
To	NULL
examine	NULL
the	NULL
nature	NULL
of	NULL
CITA	NULL
function	NULL
,	NULL
a	NULL
series	NULL
of	NULL
mutations	NULL
were	NULL
introduced	NULL
into	NULL
the	NULL
CIITA	NULL
gene	NULL
that	NULL
could	NULL
be	NULL
assayed	NULL
for	NULL
their	NULL
ability	NULL
to	NULL
distinguish	NULL
between	NULL
wild-type	NULL
and	NULL
mutant	NULL
class	NULL
II	NULL
promoters	NULL
.	NULL

Small	NULL
in-frame	NULL
deletions	NULL
beginning	NULL
3	NULL
``	NULL
of	NULL
the	NULL
acidic	NULL
activation	NULL
domain	NULL
were	NULL
created	NULL
along	NULL
the	NULL
length	NULL
of	NULL
CIITA	NULL
(	NULL
Fig	NULL
.	NULL

1	NULL
)	NULL
.	NULL

The	NULL
mutations	NULL
were	NULL
made	NULL
downstream	NULL
of	NULL
the	NULL
acidic	NULL
activation	NULL
domain	NULL
for	NULL
three	NULL
reasons	NULL
.	NULL

First	NULL
,	NULL
previous	NULL
work	NULL
had	NULL
shown	NULL
that	NULL
this	NULL
domain	NULL
was	NULL
required	NULL
for	NULL
transcriptional	NULL
activation	NULL
(	NULL
39	NULL
)	NULL
.	NULL

Second	NULL
,	NULL
the	NULL
non-functional	NULL
allele	NULL
of	NULL
CIITA	NULL
in	NULL
the	NULL
BLS	NULL
complementation	NULL
group	NULL
A	NULL
cell	NULL
line	NULL
RJ2.2.5	NULL
has	NULL
a	NULL
fully	NULL
intact	NULL
activation	NULL
domain	NULL
(	NULL
46	NULL
)	NULL
,	NULL
suggesting	NULL
that	NULL
CIITA	NULL
has	NULL
properties	NULL
in	NULL
addition	NULL
to	NULL
transcriptional	NULL
activation	NULL
.	NULL

Third	NULL
,	NULL
all	NULL
complementation	NULL
group	NULL
A	NULL
BLS	NULL
patient-derived	NULL
cell	NULL
lines	NULL
have	NULL
mutations	NULL
downstream	NULL
of	NULL
the	NULL
activation	NULL
domain	NULL
(	NULL
32,33	NULL
)	NULL
.	NULL

The	NULL
predicted	NULL
coding	NULL
region	NULL
of	NULL
CIITA	NULL
(	NULL
32	NULL
)	NULL
was	NULL
cloned	NULL
into	NULL
the	NULL
pSVK	NULL
eukaryotic	NULL
expression	NULL
vector	NULL
,	NULL
which	NULL
had	NULL
been	NULL
modified	NULL
to	NULL
contain	NULL
the	NULL
FLAG	NULL
epitope	NULL
(	NULL
IBI	NULL
,	NULL
Corning	NULL
,	NULL
NY	NULL
)	NULL
at	NULL
its	NULL
N-terminus	NULL
.	NULL

The	NULL
construction	NULL
containing	NULL
the	NULL
wild-type	NULL
CITA	NULL
sequence	NULL
was	NULL
termed	NULL
pFLAG-CIITA	NULL
.	NULL

All	NULL
other	NULL
constructs	NULL
were	NULL
based	NULL
on	NULL
this	NULL
vector	NULL
.	NULL

Of	NULL
the	NULL
engineered	NULL
mutations	NULL
,	NULL
some	NULL
were	NULL
randomly	NULL
spaced	NULL
along	NULL
the	NULL
length	NULL
of	NULL
the	NULL
CIITA	NULL
gene	NULL
,	NULL
while	NULL
others	NULL
targeted	NULL
specific	NULL
regions	NULL
that	NULL
potentially	NULL
could	NULL
affect	NULL
function	NULL
.	NULL

Two	NULL
mutants	NULL
,	NULL
A3CIITA	NULL
and	NULL
ASCIITA	NULL
,	NULL
were	NULL
designed	NULL
to	NULL
disrupt	NULL
the	NULL
G1	NULL
and	NULL
G3	NULL
boxes	NULL
,	NULL
respectively	NULL
,	NULL
of	NULL
the	NULL
putative	NULL
GTP-binding	NULL
domain	NULL
.	NULL

The	NULL
ASCIITA	NULL
deletion	NULL
also	NULL
eliminated	NULL
one	NULL
of	NULL
the	NULL
four	NULL
consensus	NULL
LCD	NULL
motifs	NULL
(	NULL
termed	NULL
L1	NULL
)	NULL
of	NULL
CHTA	NULL
.	NULL

A10CIITA	NULL
and	NULL
A11CIHITA	NULL
disrupt	NULL
a	NULL
leucine-rich	NULL
region	NULL
near	NULL
the	NULL
C-terminus	NULL
of	NULL
the	NULL
protein	NULL
.	NULL

Last	NULL
,	NULL
CHTA	NULL
(	NULL
I61-1130	NULL
)	NULL
lacks	NULL
the	NULL
activation	NULL
domain	NULL
but	NULL
retains	NULL
all	NULL
other	NULL
sequences	NULL
of	NULL
CIITA	NULL
,	NULL
including	NULL
the	NULL
P/S/T	NULL
region	NULL
.	NULL

Two	NULL
methods	NULL
were	NULL
used	NULL
to	NULL
confirm	NULL
that	NULL
the	NULL
mutant	NULL
constructs	NULL
encoded	NULL
the	NULL
desired	NULL
mutations	NULL
.	NULL

First	NULL
,	NULL
all	NULL
mutations	NULL
were	NULL
confirmed	NULL
by	NULL
DNA	NULL
sequencing	NULL
.	NULL

Second	NULL
,	NULL
each	NULL
construct	NULL
was	NULL
expressed	NULL
in	NULL
an	NULL
in	NULL
vitro	NULL
transcription/translation	NULL
reaction	NULL
to	NULL
ensure	NULL
that	NULL
the	NULL
proteins	NULL
produced	NULL
were	NULL
of	NULL
the	NULL
expected	NULL
size	NULL
(	NULL
Fig	NULL
.	NULL

2A	NULL
)	NULL
.	NULL

Because	NULL
the	NULL
FLAG	NULL
epitope	NULL
was	NULL
unable	NULL
to	NULL
be	NULL
detected	NULL
by	NULL
western	NULL
blot	NULL
when	NULL
FLAG-CIITA	NULL
was	NULL
transfected	NULL
into	NULL
RJ2.2.5	NULL
or	NULL
Raji	NULL
cells	NULL
,	NULL
a	NULL
CHTA-specific	NULL
antiserum	NULL
was	NULL
developed	NULL
to	NULL
detect	NULL
CIITA	NULL
.	NULL

Rabbit	NULL
polyclonal	NULL
antiserum	NULL
was	NULL
generated	NULL
to	NULL
an	NULL
Escherichia	NULL
coli-expressed	NULL
MBP-CIITA	NULL
chimera	NULL
.	NULL

Use	NULL
of	NULL
the	NULL
MBP-CIITA	NULL
fusion	NULL
allowed	NULL
stable	NULL
and	NULL
soluble	NULL
expression	NULL
of	NULL
CITA	NULL
in	NULL
bacteria	NULL
.	NULL

The	NULL
antiserum	NULL
recognizes	NULL
CIITA	NULL
in	NULL
the	NULL
wild-type	NULL
Raji	NULL
B	NULL
cell	NULL
line	NULL
,	NULL
but	NULL
not	NULL
in	NULL
the	NULL
CHTA-deficient	NULL
cell	NULL
line	NULL
RJ2.2.5	NULL
(	NULL
Fig	NULL
.	NULL

2B	NULL
)	NULL
.	NULL

To	NULL
determine	NULL
if	NULL
the	NULL
CHITA	NULL
mutant	NULL
series	NULL
would	NULL
be	NULL
expressed	NULL
and	NULL
stable	NULL
in	NULL
eukaryotic	NULL
cells	NULL
,	NULL
immunoblot	NULL
analysis	NULL
was	NULL
carried	NULL
out	NULL
on	NULL
RJ2.2.5	NULL
cells	NULL
transiently	NULL
transfected	NULL
with	NULL
the	NULL
mutant	NULL
CIHITA	NULL
constructs	NULL
.	NULL

The	NULL
results	NULL
show	NULL
that	NULL
the	NULL
CIITA	NULL
mutant	NULL
proteins	NULL
can	NULL
be	NULL
detected	NULL
at	NULL
24	NULL
h	NULL
after	NULL
transfection	NULL
,	NULL
suggesting	NULL
that	NULL
the	NULL
overall	NULL
levels	NULL
of	NULL
CHITA	NULL
and	NULL
the	NULL
stability	NULL
of	NULL
the	NULL
mutant	NULL
proteins	NULL
is	NULL
similar	NULL
to	NULL
the	NULL
wild-type	NULL
(	NULL
Fig	NULL
.	NULL

2C	NULL
)	NULL
.	NULL

The	NULL
CHTA	NULL
(	NULL
161-1130	NULL
)	NULL
Nucleic	NULL
Acids	NULL
Research	NULL
,	NULL
1998	NULL
,	NULL
Vol	NULL
.	NULL

26	NULL
,	NULL
No	NULL
.	NULL

18	NULL
_	NULL
4131	NULL
V	NULL
a*	NULL
.o	NULL
a	NULL
CS	NULL
“	NULL
Q	NULL
”	NULL
?	NULL

moult	NULL
$	NULL
57	NULL
A.	NULL
Vail	NULL
;	NULL
3	NULL
go	NULL
;	NULL
€	NULL
``	NULL
S	NULL
\	NULL
af	NULL
AZ	NULL
A3	NULL
A4	NULL
AS	NULL
A6	NULL
AT	NULL
AB	NULL
A9	NULL
MO	NULL
M1	NULL
A12	NULL
£	NULL
€	NULL
y	NULL
*~	NULL
#	NULL
K	NULL
B.	NULL
Mo	NULL
100	NULL
20003	NULL
2207	NULL
ap	NULL
<	NULL
@	NULL
ciita	NULL
at-69	NULL
a	NULL
$	NULL
g	NULL
``	NULL
C.	NULL
a	NULL
m	NULL
mo	NULL
3	NULL
MO	NULL
A20	NULL
A3	NULL
A40	NULL
A5	NULL
A60	NULL
A7	NULL
0	NULL
A80	NULL
A90	NULL
M10	NULL
M10	NULL
M2	NULL
o	NULL
€	NULL
€	NULL
£	NULL
$	NULL
-a	NULL
s	NULL
sith	NULL
~-	NULL
--	NULL
``	NULL
Abate	NULL
)	NULL
18s	NULL
)	NULL
Sacco	NULL
m	NULL
ss	NULL
Figure	NULL
2	NULL
.	NULL

Expression	NULL
of	NULL
CHTA	NULL
deletion	NULL
mutants	NULL
in	NULL
vitro	NULL
and	NULL
in	NULL
vivo	NULL
.	NULL

(	NULL
A	NULL
)	NULL
Autoradiograph	NULL
of	NULL
SDS-PAGE	NULL
of	NULL
CIITA	NULL
deletion	NULL
mutants	NULL
.	NULL

Aliquots	NULL
of	NULL
1	NULL
ug	NULL
of	NULL
the	NULL
indicated	NULL
CIITA	NULL
deletion	NULL
constructs	NULL
were	NULL
used	NULL
in	NULL
individual	NULL
transcription/translation	NULL
reactions	NULL
using	NULL
the	NULL
T7	NULL
RNA	NULL
polymerase	NULL
TnT	NULL
kit	NULL
(	NULL
Promega	NULL
Corp.	NULL
,	NULL
Madison	NULL
,	NULL
WI	NULL
)	NULL
as	NULL
described	NULL
by	NULL
the	NULL
manufacturer	NULL
.	NULL

(	NULL
B	NULL
)	NULL
Polyclonal	NULL
antiserum	NULL
specifically	NULL
recognizes	NULL
recombinant	NULL
CIITA	NULL
and	NULL
native	NULL
CITA	NULL
from	NULL
Raji	NULL
but	NULL
not	NULL
RJ2.2.5	NULL
cell	NULL
lysates	NULL
in	NULL
an	NULL
immunoblot	NULL
.	NULL

Lane	NULL
1	NULL
,	NULL
recombinant	NULL
CITA	NULL
(	NULL
2	NULL
ug	NULL
)	NULL
;	NULL
lane	NULL
2	NULL
,	NULL
Raji	NULL
cell	NULL
lysate	NULL
(	NULL
1.5	NULL
x	NULL
105	NULL
cells	NULL
)	NULL
;	NULL
lane	NULL
3	NULL
,	NULL
RJ2.2.5	NULL
cell	NULL
lysate	NULL
(	NULL
1.5	NULL
x	NULL
106	NULL
cells	NULL
)	NULL
.	NULL

The	NULL
arrow	NULL
indicates	NULL
the	NULL
position	NULL
of	NULL
the	NULL
CHTA-specific	NULL
band	NULL
.	NULL

(	NULL
C	NULL
)	NULL
CIITA	NULL
deletion	NULL
mutants	NULL
are	NULL
expressed	NULL
when	NULL
transiently	NULL
transfected	NULL
into	NULL
RJ2.2.5	NULL
cells	NULL
.	NULL

Aliquots	NULL
of	NULL
20	NULL
ug	NULL
CIITA	NULL
expression	NULL
constructs	NULL
were	NULL
transfected	NULL
into	NULL
RJ2.2.5	NULL
cells	NULL
as	NULL
previously	NULL
described	NULL
.	NULL

Cells	NULL
were	NULL
harvested	NULL
at	NULL
24	NULL
h	NULL
post-transfection	NULL
and	NULL
lysed	NULL
by	NULL
resuspension	NULL
in	NULL
SDS-PAGE	NULL
sample	NULL
buffer	NULL
.	NULL

Lysates	NULL
were	NULL
analyzed	NULL
by	NULL
immunoblot	NULL
as	NULL
above	NULL
.	NULL

mutant	NULL
is	NULL
either	NULL
slightly	NULL
less	NULL
stable	NULL
or	NULL
not	NULL
produced	NULL
in	NULL
the	NULL
same	NULL
quantities	NULL
as	NULL
the	NULL
others	NULL
,	NULL
as	NULL
1.5-fold	NULL
more	NULL
extract	NULL
was	NULL
required	NULL
to	NULL
generate	NULL
a	NULL
similar	NULL
signal	NULL
.	NULL

Most	NULL
mutations	NULL
in	NULL
CIITA	NULL
C-terminal	NULL
of	NULL
amino	NULL
acid	NULL
377	NULL
result	NULL
in	NULL
the	NULL
loss	NULL
of	NULL
CHTA	NULL
activity	NULL
The	NULL
ability	NULL
of	NULL
the	NULL
CIITA	NULL
mutants	NULL
to	NULL
transactivate	NULL
the	NULL
X-Y	NULL
box-dependent	NULL
CAT	NULL
reporter	NULL
plasmid	NULL
pDRG-X1-X2-Y	NULL
(	NULL
39	NULL
)	NULL
was	NULL
determined	NULL
by	NULL
co-transfection	NULL
into	NULL
RJ2.2.5	NULL
cells	NULL
.	NULL

The	NULL
FLAG	NULL
epitope	NULL
had	NULL
no	NULL
effect	NULL
on	NULL
CIITA	NULL
activity	NULL
,	NULL
as	NULL
it	NULL
gave	NULL
comparable	NULL
transactivation	NULL
of	NULL
the	NULL
reporter	NULL
as	NULL
the	NULL
previously	NULL
characterized	NULL
CIITA	NULL
expression	NULL
vector	NULL
pCIITA-8	NULL
(	NULL
39	NULL
;	NULL
Fig	NULL
.	NULL

3A	NULL
)	NULL
.	NULL

The	NULL
ability	NULL
of	NULL
the	NULL
CIITA	NULL
mutants	NULL
to	NULL
transactivate	NULL
pDRG-X1-X2-Y	NULL
was	NULL
assayed	NULL
and	NULL
normalized	NULL
to	NULL
the	NULL
level	NULL
of	NULL
expression	NULL
produced	NULL
by	NULL
the	NULL
pFLAG-CIHITA	NULL
construct	NULL
(	NULL
Fig	NULL
.	NULL

3A	NULL
)	NULL
.	NULL

Most	NULL
CIITA	NULL
mutations	NULL
resulted	NULL
in	NULL
non-functional	NULL
alleles	NULL
.	NULL

The	NULL
only	NULL
exceptions	NULL
were	NULL
the	NULL
most	NULL
N-terminal	NULL
mutations	NULL
,	NULL
A1	NULL
and	NULL
A2	NULL
,	NULL
which	NULL
both	NULL
yielded	NULL
near	NULL
wild-type	NULL
CAT	NULL
levels	NULL
as	NULL
compared	NULL
with	NULL
pFLAG-CIITA	NULL
.	NULL

Similar	NULL
results	NULL
were	NULL
obtained	NULL
when	NULL
using	NULL
CAT	NULL
reporter	NULL
constructs	NULL
driven	NULL
solely	NULL
by	NULL
the	NULL
X1-X2	NULL
sequences	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

To	NULL
determine	NULL
if	NULL
any	NULL
of	NULL
the	NULL
mutations	NULL
could	NULL
function	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
the	NULL
W	NULL
box	NULL
,	NULL
transfections	NULL
were	NULL
carried	NULL
out	NULL
using	NULL
the	NULL
previously	NULL
described	NULL
W-X-Y-dependent	NULL
reporter	NULL
construct	NULL
pDRW-X-Y	NULL
(	NULL
13	NULL
)	NULL
.	NULL

Previous	NULL
work	NULL
from	NULL
our	NULL
laboratory	NULL
indicated	NULL
that	NULL
the	NULL
levels	NULL
of	NULL
CHTA-dependent	NULL
transcription	NULL
increased	NULL
2-3-fold	NULL
when	NULL
the	NULL
W	NULL
box	NULL
was	NULL
included	NULL
in	NULL
the	NULL
promoter	NULL
(	NULL
27,39	NULL
)	NULL
.	NULL

This	NULL
was	NULL
also	NULL
the	NULL
case	NULL
for	NULL
CIITA	NULL
transactivation	NULL
in	NULL
this	NULL
system	NULL
,	NULL
as	NULL
the	NULL
reporter	NULL
levels	NULL
driven	NULL
by	NULL
pDRW-X-Y	NULL
were	NULL
3.2-fold	NULL
higher	NULL
than	NULL
those	NULL
produced	NULL
with	NULL
pDRG-X1-X2-Y	NULL
.	NULL

ASCIITA	NULL
showed	NULL
clear	NULL
differences	NULL
in	NULL
transactivation	NULL
capabilities	NULL
between	NULL
promoters	NULL
driven	NULL
by	NULL
X1-X2-Y	NULL
and	NULL
W-X-Y	NULL
.	NULL

Where	NULL
A5	NULL
was	NULL
inactive	NULL
with	NULL
an	NULL
X-Y	NULL
promoter	NULL
,	NULL
this	NULL
mutant	NULL
activated	NULL
the	NULL
W-X-Y	NULL
reporter	NULL
to	NULL
50.3	NULL
%	NULL
of	NULL
wild-type	NULL
expression	NULL
levels	NULL
.	NULL

This	NULL
differential	NULL
activity	NULL
for	NULL
A5	NULL
suggests	NULL
that	NULL
this	NULL
mutation	NULL
alters	NULL
the	NULL
structure	NULL
of	NULL
CIITA	NULL
in	NULL
such	NULL
a	NULL
manner	NULL
that	NULL
it	NULL
is	NULL
now	NULL
able	NULL
to	NULL
function	NULL
only	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
the	NULL
W	NULL
box	NULL
,	NULL
implying	NULL
that	NULL
CIITA	NULL
interacts	NULL
with	NULL
the	NULL
W	NULL
box	NULL
proteins	NULL
.	NULL

While	NULL
other	NULL
mutations	NULL
also	NULL
appear	NULL
to	NULL
show	NULL
some	NULL
W	NULL
box-dependent	NULL
activity	NULL
(	NULL
e.g	NULL
.	NULL

A7	NULL
and	NULL
A9CIITA	NULL
)	NULL
,	NULL
this	NULL
phenotype	NULL
is	NULL
most	NULL
pronounced	NULL
for	NULL
ASCIITA	NULL
.	NULL

Primary	NULL
amino	NULL
acid	NULL
homology	NULL
searches	NULL
with	NULL
CIITA	NULL
highlighted	NULL
a	NULL
potential	NULL
bipartite	NULL
nuclear	NULL
localization	NULL
sequence	NULL
(	NULL
NLS	NULL
)	NULL
in	NULL
murine	NULL
CIITA	NULL
(	NULL
47	NULL
)	NULL
and	NULL
a	NULL
conserved	NULL
potential	NULL
CDK	NULL
phosphorylation	NULL
site	NULL
[	NULL
consensus	NULL
SPxR	NULL
(	NULL
48	NULL
)	NULL
,	NULL
CIITA	NULL
positions	NULL
Ser280	NULL
,	NULL
Pro281	NULL
,	NULL
Arg283	NULL
]	NULL
.	NULL

Individual	NULL
mutations	NULL
were	NULL
created	NULL
that	NULL
deleted	NULL
the	NULL
potential	NULL
NLS	NULL
(	NULL
residues	NULL
141-160	NULL
of	NULL
human	NULL
CHTA	NULL
)	NULL
and	NULL
altered	NULL
the	NULL
conserved	NULL
residues	NULL
of	NULL
the	NULL
CDK	NULL
phosphorylation	NULL
site	NULL
to	NULL
alanines	NULL
.	NULL

Both	NULL
of	NULL
these	NULL
mutants	NULL
were	NULL
able	NULL
to	NULL
drive	NULL
transcription	NULL
to	NULL
near	NULL
wild-type	NULL
levels	NULL
in	NULL
all	NULL
assays	NULL
tested	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

Mutations	NULL
in	NULL
the	NULL
activation	NULL
domain	NULL
and	NULL
central	NULL
regions	NULL
of	NULL
CIITA	NULL
interfere	NULL
with	NULL
the	NULL
function	NULL
of	NULL
wild-type	NULL
CIITA	NULL
in	NULL
Raji	NULL
cells	NULL
Mutations	NULL
that	NULL
exhibit	NULL
dominant	NULL
negative	NULL
effects	NULL
often	NULL
result	NULL
from	NULL
the	NULL
disruption	NULL
of	NULL
a	NULL
functional	NULL
domain	NULL
of	NULL
the	NULL
protein	NULL
without	NULL
disrupting	NULL
other	NULL
portions	NULL
of	NULL
the	NULL
protein	NULL
.	NULL

This	NULL
class	NULL
of	NULL
mutants	NULL
is	NULL
able	NULL
to	NULL
interact	NULL
with	NULL
additional	NULL
factors	NULL
,	NULL
but	NULL
the	NULL
resulting	NULL
complexes	NULL
are	NULL
biologically	NULL
inactive	NULL
or	NULL
non-functional	NULL
.	NULL

To	NULL
further	NULL
analyze	NULL
the	NULL
mutant	NULL
CIITA	NULL
proteins	NULL
,	NULL
transient	NULL
co-transfections	NULL
of	NULL
the	NULL
CHTA	NULL
mutants	NULL
were	NULL
carried	NULL
out	NULL
with	NULL
the	NULL
pDRW-X-Y	NULL
reporter	NULL
in	NULL
Raji	NULL
cells	NULL
to	NULL
test	NULL
for	NULL
dominant	NULL
negative	NULL
function	NULL
of	NULL
the	NULL
mutants	NULL
.	NULL

Transfection	NULL
of	NULL
the	NULL
wild-type	NULL
FLAG-CIITA	NULL
construction	NULL
in	NULL
Raji	NULL
cells	NULL
resulted	NULL
in	NULL
an	NULL
increase	NULL
in	NULL
expression	NULL
of	NULL
the	NULL
reporter	NULL
gene	NULL
by	NULL
a	NULL
factor	NULL
of	NULL
4.5	NULL
,	NULL
indicating	NULL
that	NULL
CIITA	NULL
is	NULL
limiting	NULL
even	NULL
in	NULL
the	NULL
high	NULL
class	NULL
-expressing	NULL
cell	NULL
line	NULL
Raji	NULL
(	NULL
Fig	NULL
.	NULL

4	NULL
)	NULL
.	NULL

In	NULL
concordance	NULL
with	NULL
the	NULL
4132	NULL
Nucleic	NULL
Acids	NULL
Research	NULL
,	NULL
1998	NULL
,	NULL
Vol	NULL
.	NULL

26	NULL
,	NULL
No	NULL
.	NULL

18	NULL
A.	NULL
Fa	NULL
(	NULL
ws	NULL
}	NULL
-	NULL
[	NULL
x1	NULL
]	NULL
x2	NULL
|-	NULL
v_	NULL
M	NULL
Flag-CIITA	NULL
CIITA	NULL
SVK-Flag	NULL
0	NULL
20	NULL
40	NULL
60	NULL
80	NULL
100	NULL
120	NULL
0	NULL
20	NULL
40	NULL
60	NULL
80	NULL
100	NULL
120	NULL
Percent	NULL
Relative	NULL
Expression	NULL
Figure	NULL
3	NULL
.	NULL

Effects	NULL
of	NULL
CHTA	NULL
mutations	NULL
on	NULL
class	NULL
II	NULL
transactivation	NULL
.	NULL

CHTA~	NULL
RJ2.2.5	NULL
cells	NULL
were	NULL
used	NULL
for	NULL
transient	NULL
transfections	NULL
with	NULL
40	NULL
ug	NULL
CIITA	NULL
expression	NULL
constructs	NULL
and	NULL
20	NULL
ug	NULL
either	NULL
pDRG-X1-X2-Y	NULL
(	NULL
A	NULL
)	NULL
or	NULL
pDRW-X-Y	NULL
(	NULL
B	NULL
)	NULL
reporter	NULL
constructs	NULL
.	NULL

A	NULL
sample	NULL
of	NULL
1	NULL
ug	NULL
was	NULL
included	NULL
in	NULL
all	NULL
transfections	NULL
to	NULL
control	NULL
for	NULL
transfection	NULL
efficiency	NULL
.	NULL

Cell	NULL
lysates	NULL
were	NULL
analyzed	NULL
by	NULL
CAT	NULL
ELISA	NULL
as	NULL
described	NULL
by	NULL
the	NULL
manufacturer	NULL
(	NULL
Boehringer	NULL
Mannheim	NULL
,	NULL
Indianapolis	NULL
,	NULL
IN	NULL
)	NULL
.	NULL

Results	NULL
are	NULL
given	NULL
as	NULL
a	NULL
percentage	NULL
of	NULL
the	NULL
level	NULL
achieved	NULL
using	NULL
FLAG-CIITA	NULL
with	NULL
the	NULL
reporter	NULL
.	NULL

The	NULL
dashed	NULL
line	NULL
in	NULL
(	NULL
B	NULL
)	NULL
(	NULL
pDR	NULL
W-X-Y	NULL
)	NULL
represents	NULL
the	NULL
level	NULL
of	NULL
reporter	NULL
activity	NULL
corresponding	NULL
to	NULL
100	NULL
%	NULL
activity	NULL
of	NULL
pDRG-X1-X2-Y	NULL
in	NULL
(	NULL
A	NULL
)	NULL
.	NULL

The	NULL
data	NULL
represent	NULL
averages	NULL
from	NULL
three	NULL
independent	NULL
assays	NULL
,	NULL
with	NULL
SEM	NULL
indicated	NULL
.	NULL

transfection	NULL
data	NULL
in	NULL
RJ2.2.5	NULL
cells	NULL
shown	NULL
in	NULL
Figure	NULL
3A	NULL
,	NULL
transfection	NULL
of	NULL
A1	NULL
(	NULL
373.8	NULL
%	NULL
of	NULL
baseline	NULL
reporter	NULL
levels	NULL
)	NULL
,	NULL
A2	NULL
(	NULL
297.3	NULL
%	NULL
)	NULL
and	NULL
A5	NULL
(	NULL
188.9	NULL
%	NULL
)	NULL
resulted	NULL
in	NULL
proportional	NULL
increases	NULL
in	NULL
expression	NULL
of	NULL
the	NULL
reporter	NULL
gene	NULL
.	NULL

Transfection	NULL
of	NULL
CHITA	NULL
mutants	NULL
A3	NULL
(	NULL
57.0	NULL
%	NULL
)	NULL
,	NULL
M	NULL
(	NULL
74.5	NULL
%	NULL
)	NULL
,	NULL
A7	NULL
(	NULL
71.7	NULL
%	NULL
)	NULL
and	NULL
A8	NULL
(	NULL
70.7	NULL
%	NULL
)	NULL
resulted	NULL
in	NULL
significantly	NULL
reduced	NULL
levels	NULL
of	NULL
the	NULL
class	NULL
II	NULL
reporter	NULL
gene	NULL
in	NULL
Raji	NULL
cells	NULL
,	NULL
indicating	NULL
that	NULL
these	NULL
mutations	NULL
were	NULL
in	NULL
regions	NULL
that	NULL
affected	NULL
some	NULL
but	NULL
not	NULL
all	NULL
of	NULL
CHTA	NULL
function	NULL
.	NULL

However	NULL
,	NULL
the	NULL
most	NULL
significant	NULL
decrease	NULL
in	NULL
reporter	NULL
levels	NULL
resulted	NULL
in	NULL
transfections	NULL
receiving	NULL
CHITA	NULL
(	NULL
161-1130	NULL
)	NULL
(	NULL
30.6	NULL
%	NULL
)	NULL
,	NULL
the	NULL
mutant	NULL
lacking	NULL
the	NULL
acidic	NULL
activation	NULL
domain	NULL
.	NULL

The	NULL
CHITA	NULL
(	NULL
161-1130	NULL
)	NULL
mutant	NULL
was	NULL
expected	NULL
to	NULL
function	NULL
in	NULL
a	NULL
dominant	NULL
negative	NULL
manner	NULL
as	NULL
just	NULL
the	NULL
activation	NULL
domain	NULL
was	NULL
deleted	NULL
.	NULL

Thus	NULL
,	NULL
all	NULL
other	NULL
interactions	NULL
are	NULL
expected	NULL
to	NULL
be	NULL
functional	NULL
.	NULL

The	NULL
A3	NULL
mutation	NULL
specifically	NULL
deletes	NULL
the	NULL
G1	NULL
motif	NULL
of	NULL
a	NULL
putative	NULL
GTP-binding	NULL
domain	NULL
,	NULL
while	NULL
mutations	NULL
A4	NULL
,	NULL
A7	NULL
and	NULL
A8	NULL
are	NULL
in	NULL
regions	NULL
of	NULL
the	NULL
molecule	NULL
that	NULL
do	NULL
not	NULL
show	NULL
significant	NULL
homology	NULL
to	NULL
described	NULL
sequences	NULL
.	NULL

The	NULL
dominant	NULL
negative	NULL
nature	NULL
of	NULL
CHTA	NULL
(	NULL
I61-1130	NULL
)	NULL
is	NULL
similar	NULL
to	NULL
that	NULL
of	NULL
other	NULL
CHTA	NULL
mutants	NULL
lacking	NULL
the	NULL
activation	NULL
domain	NULL
while	NULL
retaining	NULL
downstream	NULL
sequences	NULL
(	NULL
49-51	NULL
)	NULL
.	NULL

Mutants	NULL
M4	NULL
,	NULL
A7	NULL
and	NULL
A8	NULL
are	NULL
in	NULL
regions	NULL
of	NULL
CIITA	NULL
that	NULL
to	NULL
our	NULL
knowledge	NULL
have	NULL
not	NULL
been	NULL
studied	NULL
;	NULL
these	NULL
mutants	NULL
therefore	NULL
suggest	NULL
a	NULL
functional	NULL
role	NULL
for	NULL
these	NULL
regions	NULL
of	NULL
the	NULL
molecule	NULL
.	NULL

Analysis	NULL
of	NULL
the	NULL
L1	NULL
and	NULL
L2	NULL
mutants	NULL
indicates	NULL
that	NULL
these	NULL
regions	NULL
are	NULL
required	NULL
for	NULL
CIITA	NULL
function	NULL
LCD	NULL
motifs	NULL
have	NULL
been	NULL
shown	NULL
to	NULL
facilitate	NULL
interactions	NULL
between	NULL
many	NULL
proteins	NULL
,	NULL
including	NULL
nuclear	NULL
receptors	NULL
and	NULL
their	NULL
coactivators	NULL
(	NULL
52	NULL
)	NULL
,	NULL
as	NULL
well	NULL
as	NULL
transcription	NULL
factors	NULL
and	NULL
coactivators	NULL
(	NULL
53	NULL
)	NULL
.	NULL

These	NULL
motifs	NULL
are	NULL
characterized	NULL
by	NULL
the	NULL
consensus	NULL
LxxLL	NULL
,	NULL
where	NULL
there	NULL
is	NULL
a	NULL
loose	NULL
consensus	NULL
for	NULL
charged	NULL
amino	NULL
acids	NULL
at	NULL
both	NULL
x	NULL
positions	NULL
.	NULL

Analysis	NULL
of	NULL
CIITA	NULL
revealed	NULL
four	NULL
such	NULL
sequences	NULL
.	NULL

Of	NULL
these	NULL
,	NULL
three	NULL
are	NULL
conserved	NULL
between	NULL
human	NULL
and	NULL
murine	NULL
CITA	NULL
(	NULL
47	NULL
)	NULL
.	NULL

The	NULL
A5	NULL
deletion	NULL
removed	NULL
two	NULL
potential	NULL
motifs	NULL
that	NULL
could	NULL
be	NULL
responsible	NULL
for	NULL
its	NULL
dependence	NULL
on	NULL
the	NULL
presence	NULL
of	NULL
the	NULL
W	NULL
box	NULL
for	NULL
function	NULL
.	NULL

Both	NULL
(	NULL
161-1130	NULL
)	NULL
A12	NULL
A1	NULL
M10	NULL
A9	NULL
A8	NULL
AT	NULL
A6	NULL
A5	NULL
A4	NULL
A3	NULL
A2	NULL
M	NULL
Flag-CHITA	NULL
SVK-Flag	NULL
0	NULL
100	NULL
200	NULL
300	NULL
400	NULL
500	NULL
%	NULL
Baseline	NULL
Expression	NULL
Figure	NULL
4	NULL
.	NULL

Mutations	NULL
in	NULL
CHTA	NULL
function	NULL
in	NULL
a	NULL
dominant	NULL
negative	NULL
manner	NULL
.	NULL

Transient	NULL
transfections	NULL
were	NULL
performed	NULL
introducing	NULL
20	NULL
ug	NULL
pDRW-X-Y	NULL
,	NULL
40	NULL
ug	NULL
CIITA	NULL
mutant	NULL
expression	NULL
plasmids	NULL
and	NULL
1	NULL
ug	NULL
SV	NULL
»	NULL
-Alkphos	NULL
into	NULL
CHTA*	NULL
Raji	NULL
cells	NULL
as	NULL
described	NULL
for	NULL
Figure	NULL
3	NULL
.	NULL

Cells	NULL
were	NULL
harvested	NULL
24	NULL
h	NULL
post-transfection	NULL
and	NULL
assayed	NULL
for	NULL
CAT	NULL
levels	NULL
as	NULL
described	NULL
above	NULL
.	NULL

Reporter	NULL
activity	NULL
is	NULL
expressed	NULL
as	NULL
a	NULL
percentage	NULL
of	NULL
each	NULL
mutant	NULL
compared	NULL
with	NULL
CAT	NULL
levels	NULL
in	NULL
transfections	NULL
receiving	NULL
the	NULL
control	NULL
expression	NULL
vector	NULL
(	NULL
percent	NULL
baseline	NULL
CAT	NULL
)	NULL
.	NULL

The	NULL
data	NULL
represent	NULL
averages	NULL
from	NULL
three	NULL
independent	NULL
assays	NULL
,	NULL
with	NULL
SEM	NULL
indicated	NULL
.	NULL

the	NULL
G3	NULL
region	NULL
of	NULL
the	NULL
putative	NULL
GTP-binding	NULL
domain	NULL
and	NULL
the	NULL
first	NULL
LCD	NULL
motif	NULL
(	NULL
L1	NULL
)	NULL
were	NULL
deleted	NULL
in	NULL
this	NULL
mutant	NULL
.	NULL

To	NULL
determine	NULL
if	NULL
the	NULL
W	NULL
box	NULL
dependence	NULL
of	NULL
ASCIITA	NULL
is	NULL
attributable	NULL
to	NULL
loss	NULL
of	NULL
the	NULL
L1	NULL
motif	NULL
,	NULL
a	NULL
mutational	NULL
analysis	NULL
of	NULL
L1	NULL
and	NULL
L2	NULL
was	NULL
undertaken	NULL
.	NULL

Previous	NULL
studies	NULL
indicate	NULL
that	NULL
protein-protein	NULL
interactions	NULL
directed	NULL
by	NULL
LCD	NULL
motifs	NULL
can	NULL
be	NULL
mediated	NULL
by	NULL
multiple	NULL
LCDs	NULL
grouped	NULL
together	NULL
in	NULL
proteins	NULL
(	NULL
53	NULL
)	NULL
.	NULL

For	NULL
this	NULL
reason	NULL
,	NULL
mutants	NULL
were	NULL
created	NULL
that	NULL
disrupted	NULL
both	NULL
L1	NULL
and	NULL
L2	NULL
,	NULL
which	NULL
are	NULL
separated	NULL
by	NULL
56	NULL
residues	NULL
in	NULL
the	NULL
primary	NULL
amino	NULL
acid	NULL
sequence	NULL
.	NULL

To	NULL
create	NULL
more	NULL
subtle	NULL
changes	NULL
,	NULL
alanine	NULL
residues	NULL
were	NULL
substituted	NULL
for	NULL
the	NULL
conserved	NULL
leucines	NULL
in	NULL
the	NULL
first	NULL
two	NULL
LCD	NULL
motifs	NULL
(	NULL
CIHITA-mutLl	NULL
and	NULL
A.	NULL
pa	NULL
pel-	NULL
y	NULL
Nucleic	NULL
Acids	NULL
Research	NULL
,	NULL
1998	NULL
,	NULL
Vol	NULL
.	NULL

26	NULL
,	NULL
No	NULL
.	NULL

18	NULL
-	NULL
4133	NULL
B.	NULL
A5	NULL
,	NULL
mut	NULL
L2	NULL
mut	NULL
L2	NULL
mut	NULL
L1	NULL
Flag-CIITA	NULL
SVK-Flag	NULL
|	NULL
0	NULL
_	NULL
20	NULL
40	NULL
60	NULL
80	NULL
_	NULL
100	NULL
o	NULL
20	NULL
40	NULL
_	NULL
60	NULL
80	NULL
_	NULL
100	NULL
Percent	NULL
Relative	NULL
Expression	NULL
Figure	NULL
5	NULL
.	NULL

LCD	NULL
motifs	NULL
L1	NULL
and	NULL
L2	NULL
are	NULL
required	NULL
for	NULL
full	NULL
transactivation	NULL
by	NULL
CIITA	NULL
.	NULL

Transient	NULL
transfections	NULL
were	NULL
performed	NULL
in	NULL
CHITA~	NULL
RJ2.2.5	NULL
cells	NULL
as	NULL
in	NULL
Figure	NULL
3	NULL
.	NULL

CAT	NULL
reporter	NULL
constructs	NULL
used	NULL
were	NULL
either	NULL
pDRG-X1-X2-Y	NULL
(	NULL
A	NULL
)	NULL
or	NULL
pDRW-X-Y	NULL
(	NULL
B	NULL
)	NULL
.	NULL

The	NULL
dashed	NULL
line	NULL
in	NULL
(	NULL
B	NULL
)	NULL
(	NULL
pDR	NULL
W-X-Y	NULL
)	NULL
represents	NULL
the	NULL
level	NULL
of	NULL
reporter	NULL
activity	NULL
corresponding	NULL
to	NULL
100	NULL
%	NULL
activity	NULL
in	NULL
(	NULL
A	NULL
)	NULL
(	NULL
pDRG-X1-X2-Y	NULL
)	NULL
.	NULL

The	NULL
data	NULL
represent	NULL
averages	NULL
from	NULL
three	NULL
independent	NULL
assays	NULL
,	NULL
with	NULL
SEM	NULL
indicated	NULL
.	NULL

CIHITA-mutL2	NULL
,	NULL
respectively	NULL
)	NULL
.	NULL

A	NULL
double	NULL
mutant	NULL
consisting	NULL
of	NULL
the	NULL
L2	NULL
mutation	NULL
and	NULL
the	NULL
ASCIITA	NULL
deletion	NULL
(	NULL
ASCIITA-mutL2	NULL
)	NULL
was	NULL
also	NULL
created	NULL
.	NULL

These	NULL
mutants	NULL
were	NULL
analyzed	NULL
by	NULL
in	NULL
vitro	NULL
transcription/	NULL
translation	NULL
and	NULL
immunoblot	NULL
procedures	NULL
as	NULL
for	NULL
the	NULL
deletion	NULL
mutants	NULL
.	NULL

The	NULL
expression	NULL
of	NULL
each	NULL
mutant	NULL
was	NULL
similar	NULL
to	NULL
those	NULL
described	NULL
above	NULL
(	NULL
Fig	NULL
.	NULL

2C	NULL
)	NULL
.	NULL

When	NULL
transient	NULL
transfections	NULL
into	NULL
RJ2.2.5	NULL
cells	NULL
were	NULL
performed	NULL
in	NULL
conjunction	NULL
with	NULL
both	NULL
the	NULL
pDRG-XI1-X2-Y	NULL
(	NULL
Fig	NULL
.	NULL

5A	NULL
)	NULL
and	NULL
pDRW-X-Y	NULL
(	NULL
Fig	NULL
.	NULL

5B	NULL
)	NULL
reporter	NULL
constructs	NULL
,	NULL
it	NULL
was	NULL
found	NULL
that	NULL
neither	NULL
CHTA-mutL1	NULL
nor	NULL
the	NULL
double	NULL
mutant	NULL
(	NULL
ASCHITA-mutL2	NULL
)	NULL
were	NULL
able	NULL
to	NULL
drive	NULL
transcription	NULL
from	NULL
either	NULL
promoter	NULL
.	NULL

CHITA-mutL2	NULL
displayed	NULL
activity	NULL
similar	NULL
to	NULL
A5	NULL
:	NULL
~50	NULL
%	NULL
activity	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
the	NULL
W	NULL
box	NULL
and	NULL
<	NULL
20	NULL
%	NULL
activity	NULL
when	NULL
just	NULL
the	NULL
X-Y	NULL
region	NULL
was	NULL
used	NULL
.	NULL

When	NULL
transfected	NULL
into	NULL
Raji	NULL
cells	NULL
,	NULL
the	NULL
double	NULL
mutant	NULL
was	NULL
able	NULL
to	NULL
reduce	NULL
reporter	NULL
levels	NULL
to	NULL
68.5	NULL
%	NULL
of	NULL
baseline	NULL
(	NULL
Fig	NULL
.	NULL

6	NULL
)	NULL
.	NULL

DISCUSSION	NULL
While	NULL
recent	NULL
studies	NULL
using	NULL
the	NULL
yeast	NULL
two-hybrid	NULL
approach	NULL
have	NULL
suggested	NULL
very	NULL
weak	NULL
interactions	NULL
between	NULL
CIITA	NULL
and	NULL
a	NULL
subunit	NULL
of	NULL
RFX	NULL
,	NULL
RFX5	NULL
(	NULL
54	NULL
)	NULL
,	NULL
direct	NULL
physical	NULL
interactions	NULL
between	NULL
CITA	NULL
and	NULL
the	NULL
class	NULL
II-specific	NULL
transcription	NULL
factors	NULL
have	NULL
not	NULL
been	NULL
described	NULL
.	NULL

Thus	NULL
,	NULL
if	NULL
the	NULL
activation	NULL
domain	NULL
of	NULL
CIITA	NULL
is	NULL
responsible	NULL
for	NULL
driving	NULL
expression	NULL
,	NULL
how	NULL
does	NULL
CIITA	NULL
interact	NULL
with	NULL
the	NULL
class	NULL
II	NULL
promoter	NULL
?	NULL

To	NULL
elucidate	NULL
further	NULL
the	NULL
mechanism	NULL
of	NULL
CHTA	NULL
action	NULL
,	NULL
mutations	NULL
were	NULL
created	NULL
and	NULL
assayed	NULL
for	NULL
their	NULL
ability	NULL
to	NULL
drive	NULL
transcription	NULL
or	NULL
to	NULL
interfere	NULL
with	NULL
the	NULL
function	NULL
of	NULL
wild-type	NULL
CIITA	NULL
in	NULL
transient	NULL
co-transfection	NULL
assays	NULL
.	NULL

While	NULL
many	NULL
of	NULL
the	NULL
mutants	NULL
were	NULL
inactive	NULL
,	NULL
two	NULL
mutants	NULL
displayed	NULL
the	NULL
ability	NULL
to	NULL
distinguish	NULL
between	NULL
class	NULL
II	NULL
promoter	NULL
elements	NULL
.	NULL

These	NULL
two	NULL
mutants	NULL
required	NULL
the	NULL
W	NULL
box	NULL
as	NULL
well	NULL
as	NULL
the	NULL
X	NULL
box	NULL
for	NULL
function	NULL
.	NULL

These	NULL
mutants	NULL
suggest	NULL
that	NULL
in	NULL
addition	NULL
to	NULL
the	NULL
X	NULL
box	NULL
factors	NULL
,	NULL
CIITA	NULL
normally	NULL
interacts	NULL
with	NULL
W	NULL
box	NULL
factors	NULL
.	NULL

This	NULL
finding	NULL
is	NULL
unique	NULL
in	NULL
that	NULL
these	NULL
are	NULL
the	NULL
first	NULL
examples	NULL
of	NULL
mutations	NULL
in	NULL
CIITA	NULL
that	NULL
sensitize	NULL
it	NULL
to	NULL
the	NULL
presence	NULL
of	NULL
a	NULL
promoter	NULL
element	NULL
.	NULL

When	NULL
considered	NULL
along	NULL
with	NULL
previous	NULL
work	NULL
indicating	NULL
that	NULL
CIITA	NULL
acts	NULL
through	NULL
the	NULL
X	NULL
box	NULL
A5	NULL
,	NULL
mutL2	NULL
mutL2	NULL
mutL1	NULL
Flag-CIITA	NULL
SVK-Flag	NULL
100	NULL
_	NULL
200	NULL
_	NULL
300	NULL
_	NULL
400	NULL
_	NULL
500	NULL
%	NULL
Baseline	NULL
Expression	NULL
Figure	NULL
6	NULL
.	NULL

Analysis	NULL
of	NULL
LCD	NULL
mutants	NULL
in	NULL
CIITA*	NULL
Raji	NULL
cells	NULL
.	NULL

Transient	NULL
transfection	NULL
and	NULL
analysis	NULL
were	NULL
performed	NULL
in	NULL
Raji	NULL
cells	NULL
as	NULL
described	NULL
for	NULL
Figure	NULL
4	NULL
,	NULL
using	NULL
40	NULL
ug	NULL
indicated	NULL
mutant	NULL
CIITA	NULL
constructs	NULL
.	NULL

The	NULL
data	NULL
represent	NULL
averages	NULL
from	NULL
three	NULL
independent	NULL
assays	NULL
,	NULL
with	NULL
SEM	NULL
indicated	NULL
.	NULL

(	NULL
27,39	NULL
)	NULL
,	NULL
this	NULL
result	NULL
strongly	NULL
supports	NULL
a	NULL
role	NULL
for	NULL
CIITA	NULL
at	NULL
the	NULL
promoter	NULL
as	NULL
a	NULL
frans-activator	NULL
.	NULL

The	NULL
W	NULL
box	NULL
of	NULL
class	NULL
II	NULL
promoters	NULL
is	NULL
the	NULL
least	NULL
homologous	NULL
of	NULL
the	NULL
conserved	NULL
sequences	NULL
.	NULL

It	NULL
was	NULL
first	NULL
defined	NULL
by	NULL
its	NULL
requirement	NULL
for	NULL
IFN-y	NULL
induction	NULL
of	NULL
class	NULL
II	NULL
expression	NULL
(	NULL
4,15	NULL
)	NULL
and	NULL
enhancement	NULL
of	NULL
class	NULL
II	NULL
expression	NULL
in	NULL
B	NULL
cells	NULL
(	NULL
14,16	NULL
)	NULL
.	NULL

Subregions	NULL
within	NULL
the	NULL
W	NULL
box	NULL
have	NULL
been	NULL
identified	NULL
,	NULL
termed	NULL
the	NULL
S	NULL
or	NULL
Z	NULL
box	NULL
,	NULL
that	NULL
provide	NULL
some	NULL
of	NULL
the	NULL
effect	NULL
of	NULL
the	NULL
full	NULL
W	NULL
box	NULL
region	NULL
.	NULL

Portions	NULL
of	NULL
the	NULL
S	NULL
region	NULL
of	NULL
the	NULL
DRA	NULL
gene	NULL
are	NULL
similar	NULL
to	NULL
the	NULL
X1	NULL
box	NULL
,	NULL
where	NULL
RFX	NULL
normally	NULL
binds	NULL
.	NULL

Recently	NULL
,	NULL
Jabrane-Ferrat	NULL
et	NULL
al	NULL
.	NULL

(	NULL
55	NULL
)	NULL
found	NULL
that	NULL
the	NULL
S	NULL
region	NULL
could	NULL
bind	NULL
RFX	NULL
in	NULL
vitro	NULL
,	NULL
although	NULL
weakly	NULL
.	NULL

This	NULL
interaction	NULL
was	NULL
stabilized	NULL
by	NULL
interactions	NULL
with	NULL
the	NULL
Y	NULL
box	NULL
factor	NULL
NF-Y	NULL
.	NULL

These	NULL
results	NULL
suggested	NULL
that	NULL
RFX	NULL
may	NULL
bind	NULL
to	NULL
both	NULL
the	NULL
S	NULL
and	NULL
the	NULL
X1	NULL
boxes	NULL
of	NULL
class	NULL
II	NULL
genes	NULL
.	NULL

The	NULL
isolation	NULL
of	NULL
mutant	NULL
CHTA	NULL
constructs	NULL
(	NULL
ASCIITA	NULL
and	NULL
CIITA-mutL2	NULL
)	NULL
that	NULL
require	NULL
the	NULL
W	NULL
box	NULL
in	NULL
addition	NULL
to	NULL
the	NULL
X-	NULL
Y	NULL
boxes	NULL
for	NULL
activity	NULL
suggests	NULL
that	NULL
CIITA	NULL
does	NULL
4134	NULL
Nucleic	NULL
Acids	NULL
Research	NULL
,	NULL
1998	NULL
,	NULL
Vol	NULL
.	NULL

26	NULL
,	NULL
No	NULL
.	NULL

18	NULL
CIITA	NULL
E	NULL
RFX	NULL
-	NULL
X2BP	NULL
NF-¥	NULL
WIS	NULL
Factor	NULL
+++	NULL
Figure	NULL
7	NULL
.	NULL

Model	NULL
for	NULL
transactivation	NULL
of	NULL
MHC	NULL
class	NULL
II	NULL
transcription	NULL
by	NULL
CIITA	NULL
.	NULL

Interactions	NULL
between	NULL
CIITA	NULL
and	NULL
promoter-bound	NULL
factors	NULL
at	NULL
the	NULL
W	NULL
,	NULL
X1	NULL
,	NULL
X2	NULL
and	NULL
Y	NULL
boxes	NULL
serve	NULL
to	NULL
stabilize	NULL
the	NULL
W-X-Y	NULL
complex	NULL
and	NULL
lead	NULL
to	NULL
transcriptional	NULL
transactivation	NULL
of	NULL
MHC	NULL
class	NULL
II	NULL
genes	NULL
.	NULL

Our	NULL
data	NULL
adds	NULL
to	NULL
the	NULL
current	NULL
model	NULL
of	NULL
MHC	NULL
class	NULL
II	NULL
transcriptional	NULL
regulation	NULL
by	NULL
implicating	NULL
direct	NULL
interactions	NULL
between	NULL
CIITA	NULL
and	NULL
the	NULL
W	NULL
box	NULL
,	NULL
providing	NULL
one	NULL
possible	NULL
explanation	NULL
for	NULL
W	NULL
box	NULL
involvement	NULL
in	NULL
induction	NULL
of	NULL
class	NULL
II	NULL
transcription	NULL
by	NULL
IFN-y	NULL
.	NULL

indeed	NULL
interact	NULL
with	NULL
this	NULL
region	NULL
(	NULL
Fig	NULL
.	NULL

7	NULL
)	NULL
.	NULL

These	NULL
mutations	NULL
are	NULL
not	NULL
likely	NULL
to	NULL
be	NULL
in	NULL
the	NULL
region	NULL
of	NULL
CIITA	NULL
that	NULL
interacts	NULL
with	NULL
W	NULL
box	NULL
factors	NULL
.	NULL

Alternatively	NULL
,	NULL
these	NULL
mutations	NULL
define	NULL
a	NULL
region	NULL
of	NULL
CITA	NULL
that	NULL
interacts	NULL
with	NULL
other	NULL
factors	NULL
;	NULL
the	NULL
loss	NULL
of	NULL
these	NULL
interactions	NULL
causes	NULL
the	NULL
protein	NULL
to	NULL
retain	NULL
frans-activation	NULL
capability	NULL
only	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
'stabilizing	NULL
'	NULL
interactions	NULL
with	NULL
factors	NULL
at	NULL
the	NULL
W	NULL
box	NULL
.	NULL

The	NULL
above	NULL
finding	NULL
suggests	NULL
that	NULL
in	NULL
B	NULL
cells	NULL
,	NULL
the	NULL
W	NULL
box	NULL
may	NULL
function	NULL
to	NULL
stabilize	NULL
CIITA	NULL
interactions	NULL
,	NULL
allowing	NULL
optimal	NULL
transcriptional	NULL
activation	NULL
(	NULL
Fig	NULL
.	NULL

7	NULL
)	NULL
,	NULL
thus	NULL
offering	NULL
a	NULL
molecular	NULL
explanation	NULL
for	NULL
the	NULL
requirement	NULL
for	NULL
the	NULL
W	NULL
box	NULL
for	NULL
class	NULL
II	NULL
induction	NULL
by	NULL
IFN-y	NULL
.	NULL

In	NULL
the	NULL
case	NULL
of	NULL
IFN-y	NULL
induction	NULL
in	NULL
class	NULL
II	NULL
negative	NULL
cells	NULL
,	NULL
such	NULL
as	NULL
human	NULL
fibroblasts	NULL
,	NULL
a	NULL
similar	NULL
situation	NULL
likely	NULL
exists	NULL
with	NULL
one	NULL
modification	NULL
,	NULL
i.e	NULL
.	NULL

the	NULL
steady-state	NULL
level	NULL
of	NULL
RFX	NULL
.	NULL

The	NULL
level	NULL
of	NULL
RFX5	NULL
,	NULL
a	NULL
subunit	NULL
of	NULL
RFX	NULL
,	NULL
in	NULL
human	NULL
fibroblasts	NULL
is	NULL
>	NULL
20-fold	NULL
lower	NULL
than	NULL
that	NULL
in	NULL
B	NULL
cells	NULL
(	NULL
20	NULL
)	NULL
,	NULL
suggesting	NULL
that	NULL
RFX	NULL
may	NULL
be	NULL
limiting	NULL
in	NULL
fibroblasts	NULL
.	NULL

The	NULL
W/S	NULL
box	NULL
could	NULL
provide	NULL
an	NULL
additional	NULL
binding	NULL
site	NULL
for	NULL
RFX	NULL
,	NULL
allowing	NULL
for	NULL
more	NULL
efficient	NULL
assembly	NULL
of	NULL
factors	NULL
to	NULL
class	NULL
II	NULL
promoters	NULL
.	NULL

Moreover	NULL
,	NULL
the	NULL
induction	NULL
of	NULL
CITA	NULL
by	NULL
IFN-y	NULL
may	NULL
further	NULL
increase	NULL
the	NULL
stability	NULL
of	NULL
W-X-Y	NULL
complexes	NULL
.	NULL

This	NULL
model	NULL
is	NULL
supported	NULL
by	NULL
two	NULL
lines	NULL
of	NULL
evidence	NULL
.	NULL

First	NULL
,	NULL
while	NULL
the	NULL
half-life	NULL
of	NULL
an	NULL
RFX-X2BP-NF-Y-DNA	NULL
complex	NULL
is	NULL
>	NULL
4	NULL
h	NULL
in	NULL
vitro	NULL
,	NULL
these	NULL
assays	NULL
were	NULL
carried	NULL
out	NULL
under	NULL
conditions	NULL
where	NULL
the	NULL
factors	NULL
were	NULL
not	NULL
limiting	NULL
(	NULL
56	NULL
)	NULL
.	NULL

As	NULL
RFX	NULL
concentration	NULL
is	NULL
reduced	NULL
,	NULL
the	NULL
ability	NULL
to	NULL
form	NULL
such	NULL
in	NULL
vitro	NULL
complexes	NULL
is	NULL
also	NULL
reduced	NULL
,	NULL
suggesting	NULL
that	NULL
if	NULL
one	NULL
of	NULL
the	NULL
factors	NULL
were	NULL
limiting	NULL
in	NULL
vivo	NULL
,	NULL
then	NULL
the	NULL
assembly	NULL
time	NULL
of	NULL
the	NULL
complex	NULL
may	NULL
be	NULL
increased	NULL
or	NULL
the	NULL
half-life	NULL
reduced	NULL
.	NULL

For	NULL
example	NULL
,	NULL
the	NULL
half-life	NULL
of	NULL
RFX	NULL
for	NULL
X1	NULL
box	NULL
DNA	NULL
and	NULL
X2BP	NULL
for	NULL
X2	NULL
box	NULL
DNA	NULL
in	NULL
vitro	NULL
is	NULL
~2	NULL
and	NULL
5	NULL
min	NULL
,	NULL
respectively	NULL
(	NULL
28,29,57	NULL
)	NULL
.	NULL

Second	NULL
,	NULL
in	NULL
vivo	NULL
genomic	NULL
footprinting	NULL
(	NULL
IVGF	NULL
)	NULL
of	NULL
the	NULL
W-X-Y	NULL
region	NULL
in	NULL
fibroblasts	NULL
detected	NULL
only	NULL
partially	NULL
protected	NULL
sequences	NULL
,	NULL
which	NULL
became	NULL
fully	NULL
protected	NULL
upon	NULL
IFN-y	NULL
treatment	NULL
(	NULL
58-60	NULL
)	NULL
.	NULL

Partial	NULL
occupancy	NULL
on	NULL
IVGF	NULL
indicates	NULL
that	NULL
fewer	NULL
cells	NULL
in	NULL
the	NULL
population	NULL
have	NULL
the	NULL
region	NULL
occupied	NULL
at	NULL
any	NULL
one	NULL
time	NULL
.	NULL

Thus	NULL
,	NULL
it	NULL
is	NULL
possible	NULL
that	NULL
induction	NULL
of	NULL
CIITA	NULL
by	NULL
IFN-y	NULL
in	NULL
fibroblasts	NULL
could	NULL
stabilize	NULL
the	NULL
complex	NULL
,	NULL
providing	NULL
an	NULL
enhanced	NULL
footprint	NULL
.	NULL

How	NULL
much	NULL
CHITA	NULL
is	NULL
required	NULL
to	NULL
activate	NULL
transcription	NULL
of	NULL
class	NULL
II	NULL
genes	NULL
?	NULL

At	NULL
least	NULL
nine	NULL
genes	NULL
are	NULL
activated	NULL
in	NULL
most	NULL
cells	NULL
when	NULL
CIITA	NULL
is	NULL
expressed	NULL
:	NULL
DRA/B	NULL
,	NULL
DQA/B	NULL
,	NULL
DPA/B	NULL
,	NULL
DMA/B	NULL
and	NULL
Ii	NULL
.	NULL

The	NULL
B	NULL
cell	NULL
line	NULL
Raji	NULL
expresses	NULL
high	NULL
levels	NULL
of	NULL
MHC	NULL
class	NULL
II	NULL
and	NULL
easily	NULL
detectable	NULL
levels	NULL
of	NULL
CIITA	NULL
.	NULL

Yet	NULL
,	NULL
even	NULL
in	NULL
Raji	NULL
cells	NULL
,	NULL
overexpression	NULL
of	NULL
CHITA	NULL
from	NULL
a	NULL
plasmid	NULL
results	NULL
in	NULL
a	NULL
4-fold	NULL
increase	NULL
in	NULL
expression	NULL
of	NULL
class	NULL
II	NULL
promoters	NULL
,	NULL
demonstrating	NULL
that	NULL
CIITA	NULL
is	NULL
limiting	NULL
.	NULL

Similar	NULL
experiments	NULL
by	NULL
others	NULL
have	NULL
not	NULL
shown	NULL
CIITA	NULL
to	NULL
be	NULL
limiting	NULL
in	NULL
Raji	NULL
cells	NULL
(	NULL
61	NULL
)	NULL
.	NULL

The	NULL
level	NULL
of	NULL
CIHITA	NULL
by	NULL
immunoblot	NULL
analysis	NULL
in	NULL
IFN-y	NULL
treated	NULL
fibroblasts	NULL
is	NULL
barely	NULL
detectable	NULL
using	NULL
our	NULL
current	NULL
antiserum	NULL
and	NULL
may	NULL
be	NULL
10-20	NULL
times	NULL
lower	NULL
than	NULL
in	NULL
Raji	NULL
cells	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
,	NULL
suggesting	NULL
that	NULL
small	NULL
amounts	NULL
of	NULL
CIITA	NULL
are	NULL
sufficient	NULL
to	NULL
induce	NULL
class	NULL
II	NULL
expression	NULL
.	NULL

The	NULL
fact	NULL
that	NULL
CITA	NULL
is	NULL
limiting	NULL
may	NULL
support	NULL
a	NULL
model	NULL
in	NULL
which	NULL
CIITA	NULL
transiently	NULL
associates	NULL
with	NULL
the	NULL
W-X-Y	NULL
box	NULL
factors	NULL
and	NULL
highlights	NULL
the	NULL
importance	NULL
of	NULL
CITA	NULL
forming	NULL
multiple	NULL
interactions	NULL
with	NULL
DNA-bound	NULL
factors	NULL
at	NULL
W-X-Y	NULL
.	NULL

The	NULL
identification	NULL
of	NULL
mutants	NULL
that	NULL
functionally	NULL
interfere	NULL
with	NULL
wild-type	NULL
CIITA	NULL
molecules	NULL
highlights	NULL
regions	NULL
of	NULL
importance	NULL
in	NULL
the	NULL
CIITA	NULL
molecule	NULL
.	NULL

While	NULL
the	NULL
most	NULL
straightforward	NULL
examples	NULL
of	NULL
dominant	NULL
negative	NULL
mutants	NULL
have	NULL
been	NULL
those	NULL
that	NULL
compete	NULL
with	NULL
wild-type	NULL
proteins	NULL
for	NULL
homodimer	NULL
formation	NULL
(	NULL
62	NULL
)	NULL
,	NULL
there	NULL
are	NULL
other	NULL
explanations	NULL
for	NULL
dominant	NULL
negative	NULL
mutants	NULL
that	NULL
do	NULL
not	NULL
require	NULL
the	NULL
protein	NULL
to	NULL
act	NULL
as	NULL
a	NULL
homodimer	NULL
,	NULL
such	NULL
as	NULL
deletion	NULL
of	NULL
an	NULL
activation	NULL
domain	NULL
from	NULL
a	NULL
transactivator	NULL
.	NULL

Such	NULL
a	NULL
construct	NULL
would	NULL
retain	NULL
all	NULL
other	NULL
interactions	NULL
,	NULL
yet	NULL
lose	NULL
its	NULL
ability	NULL
to	NULL
recruit	NULL
the	NULL
general	NULL
transcriptional	NULL
machinery	NULL
to	NULL
the	NULL
promoter	NULL
.	NULL

Indeed	NULL
,	NULL
this	NULL
type	NULL
of	NULL
dominant	NULL
negative	NULL
mutant	NULL
has	NULL
been	NULL
described	NULL
for	NULL
other	NULL
coactivators	NULL
,	NULL
such	NULL
as	NULL
c-Ets2	NULL
(	NULL
63	NULL
)	NULL
and	NULL
NTF-1	NULL
(	NULL
64	NULL
)	NULL
.	NULL

CHTA	NULL
(	NULL
161-1130	NULL
)	NULL
fits	NULL
this	NULL
category	NULL
of	NULL
dominant	NULL
negative	NULL
mutants	NULL
.	NULL

The	NULL
sequence	NULL
of	NULL
CHTA	NULL
between	NULL
residues	NULL
420	NULL
and	NULL
561	NULL
shows	NULL
homology	NULL
to	NULL
the	NULL
G1	NULL
,	NULL
G3	NULL
and	NULL
G4	NULL
domains	NULL
of	NULL
a	NULL
GTP-binding	NULL
motif	NULL
(	NULL
reviewed	NULL
in	NULL
65	NULL
)	NULL
.	NULL

The	NULL
A3CIITA	NULL
allele	NULL
has	NULL
a	NULL
specific	NULL
deletion	NULL
in	NULL
the	NULL
G1	NULL
domain	NULL
(	NULL
66	NULL
)	NULL
,	NULL
which	NULL
is	NULL
involved	NULL
in	NULL
phosphate	NULL
binding	NULL
,	NULL
suggesting	NULL
the	NULL
intriguing	NULL
possibility	NULL
that	NULL
CIITA	NULL
requires	NULL
GTP	NULL
for	NULL
function	NULL
.	NULL

Chin	NULL
et	NULL
al	NULL
.	NULL

(	NULL
42	NULL
)	NULL
recently	NULL
showed	NULL
that	NULL
mutation	NULL
of	NULL
the	NULL
region	NULL
corresponding	NULL
to	NULL
the	NULL
G3	NULL
motif	NULL
results	NULL
in	NULL
a	NULL
non-functional	NULL
,	NULL
dominant	NULL
negative	NULL
CITA	NULL
molecule	NULL
(	NULL
42	NULL
)	NULL
.	NULL

Attempts	NULL
to	NULL
show	NULL
GTP	NULL
and	NULL
other	NULL
nucleotide	NULL
binding	NULL
by	NULL
CIITA	NULL
were	NULL
inconclusive	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

It	NULL
is	NULL
possible	NULL
that	NULL
CIITA	NULL
binds	NULL
GTP	NULL
with	NULL
low	NULL
affinity	NULL
or	NULL
that	NULL
other	NULL
factors	NULL
are	NULL
required	NULL
for	NULL
this	NULL
binding	NULL
that	NULL
may	NULL
not	NULL
be	NULL
present	NULL
in	NULL
vitro	NULL
.	NULL

Alternatively	NULL
,	NULL
the	NULL
GTP-binding	NULL
motif	NULL
homology	NULL
may	NULL
be	NULL
coincidental	NULL
and	NULL
the	NULL
deletion	NULL
in	NULL
A3CIITA	NULL
eliminates	NULL
numerous	NULL
glycine	NULL
residues	NULL
,	NULL
which	NULL
may	NULL
provide	NULL
needed	NULL
flexibility	NULL
at	NULL
this	NULL
position	NULL
.	NULL

Comparison	NULL
of	NULL
the	NULL
function	NULL
of	NULL
some	NULL
mutants	NULL
described	NULL
underscores	NULL
the	NULL
fact	NULL
that	NULL
little	NULL
is	NULL
known	NULL
about	NULL
the	NULL
three-dimensional	NULL
structure	NULL
of	NULL
CHITA	NULL
and	NULL
hence	NULL
the	NULL
effect	NULL
of	NULL
these	NULL
mutations	NULL
on	NULL
the	NULL
protein	NULL
.	NULL

A5	NULL
and	NULL
mutL1	NULL
both	NULL
disrupt	NULL
the	NULL
L1	NULL
motif	NULL
,	NULL
the	NULL
former	NULL
with	NULL
a	NULL
10	NULL
residue	NULL
deletion	NULL
,	NULL
the	NULL
latter	NULL
with	NULL
alanine	NULL
substitutions	NULL
at	NULL
three	NULL
conserved	NULL
leucines	NULL
.	NULL

The	NULL
result	NULL
that	NULL
the	NULL
alanine	NULL
substitution	NULL
mutant	NULL
resulted	NULL
in	NULL
a	NULL
more	NULL
severe	NULL
phenotype	NULL
than	NULL
the	NULL
deletion	NULL
is	NULL
intriguing	NULL
and	NULL
could	NULL
result	NULL
from	NULL
unproductive	NULL
protein	NULL
folding	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
alanine	NULL
residues	NULL
at	NULL
the	NULL
position	NULL
of	NULL
L1	NULL
(	NULL
amino	NULL
acid	NULL
residues	NULL
465-469	NULL
)	NULL
.	NULL

Because	NULL
leucine	NULL
residues	NULL
have	NULL
a	NULL
tendency	NULL
to	NULL
be	NULL
near	NULL
the	NULL
N-terminal	NULL
ends	NULL
of	NULL
o-helical	NULL
structures	NULL
(	NULL
67	NULL
)	NULL
,	NULL
it	NULL
is	NULL
possible	NULL
that	NULL
loss	NULL
of	NULL
these	NULL
stabilizing	NULL
residues	NULL
results	NULL
in	NULL
'dead	NULL
end	NULL
'	NULL
protein	NULL
folding	NULL
and	NULL
therefore	NULL
a	NULL
more	NULL
severe	NULL
phenotype	NULL
of	NULL
mutL1	NULL
as	NULL
compared	NULL
with	NULL
ASCIHITA	NULL
.	NULL

Most	NULL
of	NULL
the	NULL
recently	NULL
described	NULL
CIITA	NULL
mutations	NULL
result	NULL
in	NULL
non-functional	NULL
proteins	NULL
,	NULL
however	NULL
,	NULL
a	NULL
small	NULL
number	NULL
produced	NULL
a	NULL
dominant	NULL
negative	NULL
effect	NULL
(	NULL
42,50	NULL
)	NULL
.	NULL

Summarizing	NULL
the	NULL
effects	NULL
of	NULL
individual	NULL
CIHTA	NULL
mutations	NULL
a	NULL
new	NULL
understanding	NULL
emerges	NULL
(	NULL
Fig	NULL
.	NULL

8	NULL
)	NULL
.	NULL

A	NULL
clear	NULL
requirement	NULL
for	NULL
the	NULL
acidic	NULL
regions	NULL
,	NULL
the	NULL
P/S/T	NULL
region	NULL
and	NULL
the	NULL
C-terminal	NULL
regions	NULL
becomes	NULL
apparent	NULL
.	NULL

However	NULL
,	NULL
there	NULL
appears	NULL
to	NULL
be	NULL
strict	NULL
boundaries	NULL
between	NULL
regions	NULL
of	NULL
the	NULL
molecule	NULL
Functional	NULL
aa	NULL
#	NULL
:	NULL
1_TAF132°	NULL
250	NULL
500	NULL
Nucleic	NULL
Acids	NULL
Research	NULL
,	NULL
1998	NULL
,	NULL
Vol	NULL
.	NULL

26	NULL
,	NULL
No	NULL
.	NULL

18	NULL
-	NULL
4135	NULL
750	NULL
1000	NULL
1130	NULL
domains	NULL
:	NULL
D/E	NULL
NLS	NULL
P/S/T	NULL
Conserved	NULL
between	NULL
human	NULL
&	NULL
1	NULL
murine	NULL
b	NULL
;	NULL
151	NULL
327	NULL
G1	NULL
GJ	NULL
L1	NULL
L2	NULL
L3	NULL
L4	NULL
LRR	NULL
815	NULL
1130	NULL
Non-functional	NULL
a	NULL
mutants	NULL
:	NULL
1E	NULL
Dominant	NULL
(	NULL
161-1130	NULL
)	NULL
negative	NULL
-h	NULL
a	NULL
mutants	NULL
:	NULL
e4	NULL
:	NULL
d	NULL
Functional	NULL
mutants	NULL
:	NULL
A13	NULL
mutCDKA1	NULL
A2	NULL
ws	NULL
G	NULL
~	NULL
me	NULL
g	NULL
eg	NULL
f	NULL
Mutants	NULL
fnquiring	NULL
W	NULL
box	NULL
for	NULL
function	NULL
:	NULL
r	NULL
tL2	NULL
ﬂ	NULL
I	NULL
'	NULL
I	NULL
'	NULL
1.LI	NULL
Figure	NULL
8	NULL
.	NULL

Comparison	NULL
of	NULL
the	NULL
described	NULL
CIITA	NULL
mutants	NULL
.	NULL

Wild-type	NULL
CIITA	NULL
with	NULL
amino	NULL
acid	NULL
positions	NULL
and	NULL
potential	NULL
functional	NULL
domains	NULL
are	NULL
indicated	NULL
.	NULL

D/E	NULL
,	NULL
acidic	NULL
domain	NULL
;	NULL
NLS	NULL
,	NULL
nuclear	NULL
localization	NULL
signal	NULL
;	NULL
P/S/T	NULL
,	NULL
Pro/Ser/Thr-rich	NULL
region	NULL
;	NULL
G1-G3	NULL
,	NULL
consensus	NULL
GTP-binding	NULL
motif	NULL
;	NULL
L1-L4	NULL
,	NULL
LCD	NULL
motifs	NULL
;	NULL
LRR	NULL
,	NULL
leucine-rich	NULL
region	NULL
.	NULL

The	NULL
regions	NULL
of	NULL
homology	NULL
between	NULL
human	NULL
and	NULL
murine	NULL
CIITA	NULL
genes	NULL
are	NULL
indicated	NULL
by	NULL
shaded	NULL
boxes	NULL
(	NULL
47	NULL
)	NULL
.	NULL

Published	NULL
mutations	NULL
of	NULL
CIITA	NULL
are	NULL
grouped	NULL
according	NULL
to	NULL
the	NULL
described	NULL
functional	NULL
levels	NULL
for	NULL
each	NULL
mutant	NULL
.	NULL

Mutants	NULL
described	NULL
herein	NULL
are	NULL
labeled	NULL
.	NULL

Notation	NULL
for	NULL
mutants	NULL
is	NULL
as	NULL
follows	NULL
:	NULL
all	NULL
horizontal	NULL
bars	NULL
represent	NULL
regions	NULL
deleted	NULL
from	NULL
full-length	NULL
CIITA	NULL
constructs	NULL
;	NULL
®	NULL
,	NULL
amino	NULL
acid	NULL
substitutions	NULL
at	NULL
that	NULL
position	NULL
of	NULL
the	NULL
protein	NULL
.	NULL

Mutants	NULL
that	NULL
were	NULL
created	NULL
and	NULL
characterized	NULL
outside	NULL
this	NULL
report	NULL
are	NULL
shaded	NULL
and	NULL
described	NULL
:	NULL
a	NULL
(	NULL
68	NULL
)	NULL
;	NULL
b	NULL
(	NULL
47	NULL
)	NULL
;	NULL
c	NULL
(	NULL
61	NULL
)	NULL
;	NULL
d	NULL
(	NULL
49	NULL
)	NULL
;	NULL
e	NULL
(	NULL
50	NULL
)	NULL
;	NULL
f	NULL
(	NULL
42	NULL
)	NULL
;	NULL
g	NULL
(	NULL
69	NULL
)	NULL
;	NULL
h	NULL
(	NULL
51	NULL
)	NULL
.	NULL

that	NULL
can	NULL
be	NULL
mutated	NULL
while	NULL
still	NULL
retaining	NULL
enough	NULL
function	NULL
to	NULL
act	NULL
in	NULL
a	NULL
dominant	NULL
negative	NULL
manner	NULL
,	NULL
both	NULL
at	NULL
the	NULL
N-	NULL
and	NULL
C-termini	NULL
of	NULL
CHTA	NULL
.	NULL

Comparison	NULL
of	NULL
mutants	NULL
surrounding	NULL
the	NULL
putative	NULL
GTP-binding	NULL
domain	NULL
is	NULL
interesting	NULL
in	NULL
that	NULL
mutations	NULL
within	NULL
this	NULL
region	NULL
are	NULL
capable	NULL
of	NULL
yielding	NULL
non-functional	NULL
,	NULL
dominant	NULL
negative	NULL
and	NULL
functional	NULL
CIITA	NULL
molecules	NULL
.	NULL

Indeed	NULL
,	NULL
similar	NULL
mutants	NULL
have	NULL
been	NULL
shown	NULL
to	NULL
have	NULL
discordant	NULL
results	NULL
in	NULL
transactivation	NULL
assays	NULL
:	NULL
ASCIITA	NULL
exhibits	NULL
the	NULL
ability	NULL
to	NULL
transactivate	NULL
in	NULL
a	NULL
W	NULL
box-dependent	NULL
manner	NULL
,	NULL
while	NULL
a	NULL
smaller	NULL
deletion	NULL
of	NULL
solely	NULL
the	NULL
G3	NULL
residues	NULL
[	NULL
CHTA-GTP2	NULL
(	NULL
ADAYG	NULL
)	NULL
;	NULL
42	NULL
]	NULL
has	NULL
no	NULL
activity	NULL
and	NULL
has	NULL
been	NULL
shown	NULL
to	NULL
have	NULL
a	NULL
dominant	NULL
negative	NULL
effect	NULL
.	NULL

A	NULL
majority	NULL
of	NULL
mutants	NULL
that	NULL
disrupt	NULL
regions	NULL
conserved	NULL
between	NULL
human	NULL
and	NULL
murine	NULL
CHITA	NULL
result	NULL
in	NULL
non-functional	NULL
or	NULL
dominant	NULL
negative	NULL
phenotypes	NULL
,	NULL
indicating	NULL
that	NULL
the	NULL
structure	NULL
of	NULL
CIITA	NULL
is	NULL
highly	NULL
conserved	NULL
between	NULL
species	NULL
.	NULL

It	NULL
is	NULL
interesting	NULL
that	NULL
the	NULL
P/S/T	NULL
domain	NULL
is	NULL
not	NULL
conserved	NULL
,	NULL
yet	NULL
this	NULL
region	NULL
is	NULL
required	NULL
for	NULL
function	NULL
of	NULL
the	NULL
human	NULL
gene	NULL
;	NULL
an	NULL
analysis	NULL
of	NULL
the	NULL
role	NULL
of	NULL
non-conserved	NULL
regions	NULL
of	NULL
the	NULL
murine	NULL
protein	NULL
may	NULL
lead	NULL
to	NULL
insights	NULL
into	NULL
the	NULL
role	NULL
of	NULL
the	NULL
P/S/T	NULL
domain	NULL
in	NULL
the	NULL
function	NULL
of	NULL
CHITA	NULL
.	NULL

ACKNOWLEDGEMENTS	NULL
We	NULL
thank	NULL
Drs	NULL
K.	NULL
Wilkinson	NULL
,	NULL
G.	NULL
Churchward	NULL
,	NULL
D.	NULL
Danner	NULL
,	NULL
D.	NULL
Reines	NULL
,	NULL
R.	NULL
Kahn	NULL
and	NULL
I.	NULL
Lopez	NULL
for	NULL
helpful	NULL
discussions	NULL
and	NULL
critical	NULL
evaluation	NULL
during	NULL
the	NULL
course	NULL
of	NULL
this	NULL
work	NULL
and	NULL
B	NULL
.	NULL

Merchant	NULL
for	NULL
editorial	NULL
assistance	NULL
.	NULL

The	NULL
work	NULL
was	NULL
supported	NULL
by	NULL
NIH	NULL
grant	NULL
AI34000	NULL
(	NULL
J.M.B	NULL
.	NULL
)	NULL

and	NULL
in	NULL
part	NULL
by	NULL
a	NULL
pre-doctoral	NULL
NIH	NULL
training	NULL
grant	NULL
(	NULL
J.A.B	NULL
.	NULL
)	NULL

.	NULL

REFERENCES	NULL
1	NULL
Unanue	NULL
,	NULL
E.R	NULL
.	NULL

,	NULL
Harding	NULL
,	NULL
C.V.	NULL
,	NULL
Luescher	NULL
,	NULL
LF	NULL
.	NULL

and	NULL
Roof	NULL
,	NULL
R.W	NULL
.	NULL

(	NULL
1989	NULL
)	NULL
Cold	NULL
Spring	NULL
Harbor	NULL
Symp	NULL
.	NULL

Quant	NULL
.	NULL

Biol	NULL
.	NULL

,	NULL
54	NULL
,	NULL
383-392	NULL
.	NULL

2	NULL
Pober	NULL
,	NULL
J.S	NULL
.	NULL

,	NULL
Collins	NULL
,	NULL
T.	NULL
,	NULL
Gimbone	NULL
,	NULL
M.A	NULL
.	NULL

,	NULL
Jr	NULL
,	NULL
Cotran	NULL
,	NULL
R.S	NULL
.	NULL

,	NULL
Gitlin	NULL
,	NULL
J.D	NULL
.	NULL

,	NULL
Fiers	NULL
,	NULL
W.	NULL
,	NULL
Clayberber	NULL
,	NULL
C.	NULL
,	NULL
Krensky	NULL
,	NULL
A.M.	NULL
,	NULL
Burakoff	NULL
,	NULL
S.J	NULL
.	NULL

and	NULL
Reiss	NULL
,	NULL
C.S	NULL
.	NULL

(	NULL
1983	NULL
)	NULL
Nature	NULL
,	NULL
305	NULL
,	NULL
726-729.	NULL
p	NULL
u	NULL
go	NULL
~1	NULL
on	NULL
tn	NULL
21	NULL
22	NULL
23	NULL
24	NULL
25	NULL
27	NULL
Glimcher	NULL
,	NULL
L.H	NULL
.	NULL

and	NULL
Kara	NULL
,	NULL
C.J	NULL
.	NULL

(	NULL
1992	NULL
)	NULL
Annu	NULL
.	NULL

Rev	NULL
.	NULL

Immunol	NULL
.	NULL

,	NULL
10	NULL
,	NULL
13-50	NULL
.	NULL

Boss	NULL
,	NULL
J.M	NULL
.	NULL

and	NULL
Strominger	NULL
,	NULL
J.L	NULL
.	NULL

(	NULL
1986	NULL
)	NULL
Proc	NULL
.	NULL

Natl	NULL
Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
,	NULL
83	NULL
,	NULL
9139-9143	NULL
.	NULL

Basta	NULL
,	NULL
PV	NULL
.	NULL

,	NULL
Sherman	NULL
,	NULL
P.A	NULL
.	NULL

and	NULL
Ting.J.P	NULL
.	NULL

(	NULL
1987	NULL
)	NULL
J	NULL
.	NULL

Immunol	NULL
.	NULL

,	NULL
138	NULL
,	NULL
1275-1280	NULL
.	NULL

Boss	NULL
,	NULL
J.M	NULL
.	NULL

(	NULL
1997	NULL
)	NULL
Curr	NULL
:	NULL
Opin	NULL
.	NULL

Immunol	NULL
.	NULL

,	NULL
9	NULL
,	NULL
107-113	NULL
.	NULL

Mach	NULL
,	NULL
B.	NULL
,	NULL
Steimle	NULL
,	NULL
V	NULL
.	NULL

and	NULL
Reith	NULL
,	NULL
W.	NULL
(	NULL
1994	NULL
)	NULL
Immunol	NULL
.	NULL

Rev	NULL
.	NULL

,	NULL
138	NULL
,	NULL
207-221.	NULL
de	NULL
Preval	NULL
,	NULL
C.	NULL
,	NULL
Lisowska-Grospierre	NULL
,	NULL
B.	NULL
,	NULL
Loche	NULL
,	NULL
M.	NULL
,	NULL
Griscelli	NULL
,	NULL
C	NULL
.	NULL

and	NULL
Mach	NULL
,	NULL
B	NULL
.	NULL

(	NULL
1985	NULL
)	NULL
Nature	NULL
,	NULL
318	NULL
,	NULL
291-293	NULL
.	NULL

Griscelli	NULL
,	NULL
C.	NULL
,	NULL
Lisowska-Grospierre	NULL
,	NULL
B	NULL
.	NULL

and	NULL
Mach	NULL
,	NULL
B	NULL
.	NULL

(	NULL
1989	NULL
)	NULL
Immunodeficiency	NULL
Rev	NULL
.	NULL

,	NULL
1	NULL
,	NULL
135-153	NULL
.	NULL

Benichou	NULL
,	NULL
B	NULL
.	NULL

and	NULL
Strominger	NULL
,	NULL
J.L	NULL
.	NULL

(	NULL
1991	NULL
)	NULL
Proc	NULL
.	NULL

Naf	NULL
!	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
,	NULL
88	NULL
,	NULL
4285-4288	NULL
.	NULL

SeidL	NULL
,	NULL
C.	NULL
,	NULL
Saraiya	NULL
,	NULL
C.	NULL
,	NULL
Osterweil	NULL
,	NULL
Z.	NULL
,	NULL
Fu	NULL
,	NULL
Y.P	NULL
.	NULL

and	NULL
Lee	NULL
,	NULL
J.S	NULL
.	NULL

(	NULL
1992	NULL
)	NULL
J	NULL
.	NULL

Immunol	NULL
.	NULL

,	NULL
148	NULL
,	NULL
1576-1584	NULL
.	NULL

Benoist	NULL
,	NULL
C	NULL
.	NULL

and	NULL
Mathis	NULL
,	NULL
D	NULL
.	NULL

(	NULL
1990	NULL
)	NULL
Annu	NULL
.	NULL

Rev	NULL
.	NULL

Immunol	NULL
.	NULL

,	NULL
8	NULL
,	NULL
681-715	NULL
.	NULL

Hasegawa	NULL
,	NULL
S.L	NULL
.	NULL

,	NULL
Riley	NULL
,	NULL
J.L	NULL
.	NULL

,	NULL
Sloan	NULL
,	NULL
J.H	NULL
.	NULL

and	NULL
Boss	NULL
,	NULL
J.M	NULL
.	NULL

(	NULL
1993	NULL
)	NULL
J	NULL
.	NULL

Immunol	NULL
.	NULL

,	NULL
150	NULL
,	NULL
1781-1793	NULL
.	NULL

Sloan	NULL
,	NULL
J.H	NULL
.	NULL

,	NULL
Hasegawa	NULL
,	NULL
S.L	NULL
.	NULL

and	NULL
Boss	NULL
,	NULL
J.M	NULL
.	NULL

(	NULL
1992	NULL
)	NULL
J	NULL
.	NULL

Immunol	NULL
.	NULL

,	NULL
148	NULL
,	NULL
2591-2599	NULL
.	NULL

Tsang	NULL
,	NULL
S.Y	NULL
.	NULL

,	NULL
Nakanishi	NULL
,	NULL
M.	NULL
and	NULL
Peterlin	NULL
,	NULL
B.M	NULL
.	NULL

(	NULL
1988	NULL
)	NULL
Proc	NULL
.	NULL

Natl	NULL
Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
,	NULL
85	NULL
,	NULL
8598-8602	NULL
.	NULL

Cogswell	NULL
,	NULL
J.P.	NULL
,	NULL
Austin	NULL
,	NULL
)	NULL
.	NULL

and	NULL
Ting.J.P	NULL
.	NULL

(	NULL
1991	NULL
)	NULL
J	NULL
.	NULL

Immunol	NULL
.	NULL

,	NULL
146	NULL
,	NULL
1361-1367	NULL
.	NULL

Basta	NULL
,	NULL
P.V	NULL
.	NULL

,	NULL
Sherman	NULL
,	NULL
P.A	NULL
.	NULL

and	NULL
Ting.J.P	NULL
.	NULL

(	NULL
1988	NULL
)	NULL
Proc	NULL
.	NULL

Natl	NULL
Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
,	NULL
85	NULL
,	NULL
8618-8622	NULL
.	NULL

Jabrane-Ferrat	NULL
,	NULL
N.	NULL
,	NULL
Fontes	NULL
,	NULL
J.D	NULL
.	NULL

,	NULL
Boss	NULL
,	NULL
J.M	NULL
.	NULL

and	NULL
Peterlin	NULL
,	NULL
B.M	NULL
.	NULL

(	NULL
1996	NULL
)	NULL
Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

,	NULL
16	NULL
,	NULL
4683-4690	NULL
.	NULL

Wright	NULL
,	NULL
K.L	NULL
.	NULL

(	NULL
1988	NULL
)	NULL
Proc	NULL
.	NULL

Natl	NULL
Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
,	NULL
85	NULL
,	NULL
8186-8190	NULL
.	NULL

Moreno	NULL
,	NULL
C.S	NULL
.	NULL

,	NULL
Rogers	NULL
,	NULL
E.M.	NULL
,	NULL
Brown	NULL
,	NULL
J	NULL
.	NULL

A.	NULL
and	NULL
Boss	NULL
,	NULL
J.M	NULL
.	NULL

(	NULL
1997	NULL
)	NULL
J	NULL
.	NULL

Immunol	NULL
.	NULL

,	NULL
158	NULL
,	NULL
5841-5848	NULL
.	NULL

Steimle	NULL
,	NULL
V.	NULL
,	NULL
Durand	NULL
,	NULL
B.	NULL
,	NULL
Emmanuele	NULL
,	NULL
B.	NULL
,	NULL
Zufferey	NULL
,	NULL
M.	NULL
,	NULL
Hadam	NULL
,	NULL
M.R	NULL
.	NULL

,	NULL
Mach	NULL
,	NULL
B	NULL
.	NULL

and	NULL
Reith	NULL
,	NULL
W.	NULL
(	NULL
1995	NULL
)	NULL
Genes	NULL
Dev	NULL
.	NULL

,	NULL
9	NULL
,	NULL
1021-1032	NULL
.	NULL

Stimac	NULL
,	NULL
E.	NULL
,	NULL
Urieli-Shoval	NULL
,	NULL
S.	NULL
,	NULL
Kempin	NULL
,	NULL
$	NULL
.	NULL

and	NULL
Pious	NULL
,	NULL
D	NULL
.	NULL

(	NULL
1991	NULL
)	NULL
J	NULL
.	NULL

Immunol	NULL
.	NULL

,	NULL
146	NULL
,	NULL
4398-4405	NULL
.	NULL

Reith	NULL
,	NULL
W.	NULL
,	NULL
Satola	NULL
,	NULL
S.	NULL
,	NULL
Herreo-Sanchez.C	NULL
.	NULL

,	NULL
Amaldi	NULL
,	NULL
L.	NULL
,	NULL
Lisowska-Grospierre	NULL
,	NULL
B.	NULL
,	NULL
Griscelli	NULL
,	NULL
C.	NULL
,	NULL
Hadam	NULL
,	NULL
M.R	NULL
.	NULL

and	NULL
Mach	NULL
,	NULL
B	NULL
.	NULL

(	NULL
1988	NULL
)	NULL
Cell	NULL
,	NULL
53	NULL
,	NULL
897-906	NULL
.	NULL

Herrero-Sanchez	NULL
,	NULL
C.	NULL
,	NULL
Reith	NULL
,	NULL
W.	NULL
,	NULL
Silacci	NULL
,	NULL
P	NULL
.	NULL

and	NULL
Mach	NULL
,	NULL
B	NULL
.	NULL

(	NULL
1992	NULL
)	NULL
Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

,	NULL
12	NULL
,	NULL
4076-4083	NULL
.	NULL

Durand	NULL
,	NULL
B.	NULL
,	NULL
Sperisen	NULL
,	NULL
P.	NULL
,	NULL
Emery	NULL
,	NULL
P.	NULL
,	NULL
Barras	NULL
,	NULL
E.	NULL
,	NULL
Zufferey	NULL
,	NULL
M.	NULL
,	NULL
Mach	NULL
,	NULL
B	NULL
.	NULL

and	NULL
Reith	NULL
,	NULL
W.	NULL
(	NULL
1997	NULL
)	NULL
EMBO	NULL
J.	NULL
,	NULL
16	NULL
,	NULL
1045-1055	NULL
.	NULL

Hasegawa	NULL
,	NULL
S.L	NULL
.	NULL

and	NULL
Boss	NULL
,	NULL
J.M	NULL
.	NULL

(	NULL
1991	NULL
)	NULL
Nucleic	NULL
Acids	NULL
Res	NULL
.	NULL

,	NULL
19	NULL
,	NULL
6269-6276	NULL
.	NULL

Riley	NULL
,	NULL
J.L	NULL
.	NULL

and	NULL
Boss	NULL
,	NULL
J.M	NULL
.	NULL

(	NULL
1993	NULL
)	NULL
J	NULL
.	NULL

Immunol	NULL
.	NULL

,	NULL
151	NULL
,	NULL
6942-6953	NULL
.	NULL

4136	NULL
Nucleic	NULL
Acids	NULL
Research	NULL
,	NULL
1998	NULL
,	NULL
Vol	NULL
.	NULL

26	NULL
,	NULL
No	NULL
.	NULL

18	NULL
28	NULL
29	NULL
30	NULL
31	NULL
32	NULL
33	NULL
34	NULL
35	NULL
36	NULL
37	NULL
38	NULL
39	NULL
40	NULL
41	NULL
42	NULL
43	NULL
44	NULL
45	NULL
46	NULL
47	NULL
48	NULL
Reith	NULL
,	NULL
W.	NULL
,	NULL
Kobr	NULL
,	NULL
M.	NULL
,	NULL
Emery	NULL
,	NULL
P.	NULL
,	NULL
Durand	NULL
,	NULL
B.	NULL
,	NULL
Siegrist	NULL
,	NULL
C.-A	NULL
.	NULL

and	NULL
Mach	NULL
,	NULL
B	NULL
.	NULL

(	NULL
1994	NULL
)	NULL
J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

,	NULL
269	NULL
,	NULL
20020-20025	NULL
.	NULL

Moreno	NULL
,	NULL
C.S	NULL
.	NULL

,	NULL
Emery	NULL
,	NULL
P.	NULL
,	NULL
West	NULL
,	NULL
J.E	NULL
.	NULL

,	NULL
Durand	NULL
,	NULL
B.	NULL
,	NULL
Reith	NULL
,	NULL
W.	NULL
,	NULL
Mach	NULL
,	NULL
B	NULL
.	NULL

and	NULL
Boss	NULL
,	NULL
J.M	NULL
.	NULL

(	NULL
1995	NULL
)	NULL
J	NULL
.	NULL

Immunol	NULL
.	NULL

,	NULL
155	NULL
,	NULL
4313-4321	NULL
.	NULL

Hooft	NULL
van	NULL
Huijsduijnen	NULL
,	NULL
R.A.	NULL
,	NULL
Li	NULL
,	NULL
X.	NULL
Y.	NULL
,	NULL
Black	NULL
,	NULL
D.	NULL
,	NULL
Maithes	NULL
,	NULL
H.	NULL
,	NULL
Benoist	NULL
,	NULL
C	NULL
.	NULL

and	NULL
Mathis	NULL
,	NULL
D	NULL
.	NULL

(	NULL
1990	NULL
)	NULL
EMBO	NULL
J.	NULL
,	NULL
9	NULL
,	NULL
3119-3127	NULL
.	NULL

Louis-Plence	NULL
,	NULL
P.	NULL
,	NULL
Moreno	NULL
,	NULL
C.S	NULL
.	NULL

and	NULL
Boss	NULL
,	NULL
J.M	NULL
.	NULL

(	NULL
1997	NULL
)	NULL
J	NULL
.	NULL

Immunol	NULL
.	NULL

,	NULL
159	NULL
,	NULL
3899-3909	NULL
.	NULL

Steimle	NULL
,	NULL
V.	NULL
,	NULL
Otten	NULL
,	NULL
L.A.	NULL
,	NULL
Zufferey	NULL
,	NULL
M	NULL
.	NULL

and	NULL
Mach	NULL
,	NULL
B	NULL
.	NULL

(	NULL
1993	NULL
)	NULL
Cell	NULL
,	NULL
75	NULL
,	NULL
135-146	NULL
.	NULL

Chin	NULL
,	NULL
K.-C.	NULL
,	NULL
Mao	NULL
,	NULL
C.	NULL
,	NULL
Skinner	NULL
,	NULL
C.	NULL
,	NULL
Riley	NULL
,	NULL
J.L	NULL
.	NULL

,	NULL
Wright	NULL
,	NULL
Moreno	NULL
,	NULL
C.	NULL
$	NULL
S.	NULL
,	NULL
Stark	NULL
,	NULL
Boss	NULL
,	NULL
J.M	NULL
.	NULL

and	NULL
Ting	NULL
.	NULL

,	NULL
J.P.-Y	NULL
.	NULL

(	NULL
1994	NULL
)	NULL
Immunity	NULL
,	NULL
1	NULL
,	NULL
687-697	NULL
.	NULL

Steimle	NULL
,	NULL
V.	NULL
,	NULL
Siegrist	NULL
,	NULL
C.-A	NULL
.	NULL

,	NULL
Mottet	NULL
,	NULL
A.	NULL
,	NULL
Lisowska-Grospierre	NULL
,	NULL
B	NULL
.	NULL

and	NULL
Mach	NULL
,	NULL
B	NULL
.	NULL

(	NULL
1994	NULL
)	NULL
Science	NULL
,	NULL
265	NULL
,	NULL
106-108	NULL
.	NULL

Silacci	NULL
,	NULL
P.	NULL
,	NULL
Mottet	NULL
,	NULL
A.	NULL
,	NULL
Steimle	NULL
,	NULL
V.	NULL
,	NULL
Reith	NULL
,	NULL
W.	NULL
and	NULL
Mach	NULL
,	NULL
B	NULL
.	NULL

(	NULL
1994	NULL
)	NULL
J.	NULL
Exp	NULL
.	NULL

Med	NULL
.	NULL

,	NULL
180	NULL
,	NULL
1329-1336	NULL
.	NULL

Chang	NULL
,	NULL
C.-H.	NULL
,	NULL
Fodor	NULL
,	NULL
W.L	NULL
.	NULL

and	NULL
Flavell	NULL
,	NULL
R.A	NULL
.	NULL

(	NULL
1992	NULL
)	NULL
J.	NULL
Exp	NULL
.	NULL

Med	NULL
.	NULL

,	NULL
176	NULL
,	NULL
1465-1469	NULL
.	NULL

Chang	NULL
,	NULL
C.-H.	NULL
,	NULL
Fontes	NULL
,	NULL
J.D	NULL
.	NULL

,	NULL
Peterlin	NULL
,	NULL
B.M	NULL
.	NULL

and	NULL
Flavell	NULL
,	NULL
R.A	NULL
.	NULL

(	NULL
1994	NULL
)	NULL
J.	NULL
Exp	NULL
.	NULL

Med	NULL
.	NULL

,	NULL
180	NULL
,	NULL
1367-1374	NULL
.	NULL

Kijeldgaard	NULL
,	NULL
M	NULL
,	NULL
Nyborg	NULL
,	NULL
J	NULL
.	NULL

and	NULL
Clark	NULL
,	NULL
B.F	NULL
.	NULL

(	NULL
1996	NULL
)	NULL
FASEB	NULL
J.	NULL
,	NULL
10	NULL
,	NULL
1347-1367	NULL
.	NULL

Riley	NULL
,	NULL
J.L	NULL
.	NULL

,	NULL
Westerheide,8.D	NULL
.	NULL

,	NULL
Price	NULL
,	NULL
J	NULL
.	NULL

A.	NULL
,	NULL
Brown	NULL
,	NULL
J	NULL
.	NULL

A.	NULL
and	NULL
Boss	NULL
,	NULL
J.M	NULL
.	NULL

(	NULL
1995	NULL
)	NULL
Immunity	NULL
,	NULL
2	NULL
,	NULL
533-543	NULL
.	NULL

Zhou	NULL
,	NULL
H	NULL
.	NULL

and	NULL
Glimcher	NULL
,	NULL
L.H	NULL
.	NULL

(	NULL
1995	NULL
)	NULL
Immunity	NULL
,	NULL
2	NULL
,	NULL
545-553	NULL
.	NULL

Mahanta	NULL
,	NULL
S.K	NULL
.	NULL

,	NULL
Scholl	NULL
,	NULL
T.	NULL
,	NULL
Yang	NULL
,	NULL
F.-C.	NULL
and	NULL
Strominger	NULL
,	NULL
J.L	NULL
.	NULL

(	NULL
1997	NULL
)	NULL
Proc	NULL
.	NULL

Natl	NULL
Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
,	NULL
94	NULL
,	NULL
6324-6329	NULL
.	NULL

Chin	NULL
,	NULL
K.-C.	NULL
,	NULL
L1	NULL
,	NULL
G.G.-X	NULL
.	NULL

and	NULL
Ting	NULL
,	NULL
J.P.-Y	NULL
.	NULL

(	NULL
1997	NULL
)	NULL
Proc	NULL
.	NULL

Natl	NULL
Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
,	NULL
94	NULL
,	NULL
2501-2506	NULL
.	NULL

Epstein	NULL
,	NULL
M.A	NULL
.	NULL

,	NULL
Achong	NULL
,	NULL
B.G	NULL
.	NULL

,	NULL
Barr	NULL
,	NULL
Y.M	NULL
.	NULL

,	NULL
Zajac	NULL
,	NULL
B.	NULL
,	NULL
Henle	NULL
,	NULL
G	NULL
.	NULL

and	NULL
Henle	NULL
,	NULL
W.	NULL
(	NULL
1966	NULL
)	NULL
J.	NULL
Natl	NULL
Cancer	NULL
.	NULL

Inst	NULL
.	NULL

,	NULL
37	NULL
,	NULL
547-559	NULL
.	NULL

Accolla	NULL
,	NULL
R.S	NULL
.	NULL

(	NULL
1983	NULL
)	NULL
J.	NULL
Exp	NULL
.	NULL

Med	NULL
.	NULL

,	NULL
157	NULL
,	NULL
1053-1058	NULL
.	NULL

Towbin	NULL
,	NULL
H.	NULL
,	NULL
Stachelin	NULL
,	NULL
T	NULL
.	NULL

and	NULL
Gordon	NULL
,	NULL
J	NULL
.	NULL

(	NULL
1979	NULL
)	NULL
Proc	NULL
.	NULL

Natl	NULL
Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
,	NULL
76	NULL
,	NULL
4350-4354	NULL
.	NULL

Brown	NULL
,	NULL
J	NULL
.	NULL

A.	NULL
,	NULL
He	NULL
,	NULL
X.-F.	NULL
,	NULL
Westerheide,8.D	NULL
.	NULL

and	NULL
Boss	NULL
,	NULL
J.M	NULL
.	NULL

(	NULL
1995	NULL
)	NULL
Immunogenetics	NULL
,	NULL
43	NULL
,	NULL
88-91	NULL
.	NULL

Sims	NULL
,	NULL
T.N	NULL
.	NULL

,	NULL
Elliott	NULL
,	NULL
J.F	NULL
.	NULL

,	NULL
Ramassar	NULL
,	NULL
V.	NULL
,	NULL
Denney	NULL
,	NULL
D	NULL
.	NULL

W.	NULL
and	NULL
Halloran	NULL
,	NULL
PF	NULL
.	NULL

(	NULL
1997	NULL
)	NULL
Immunogenetics	NULL
,	NULL
45	NULL
,	NULL
220-222	NULL
.	NULL

Trzepacz	NULL
,	NULL
C.	NULL
,	NULL
Lowy	NULL
,	NULL
A.M.	NULL
,	NULL
Kordich	NULL
,	NULL
J.J	NULL
.	NULL

and	NULL
Groden	NULL
,	NULL
J	NULL
.	NULL

(	NULL
1997	NULL
)	NULL
J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

,	NULL
272	NULL
,	NULL
21681-21684	NULL
.	NULL

49	NULL
50	NULL
51	NULL
53	NULL
54	NULL
55	NULL
56	NULL
57	NULL
58	NULL
59	NULL
60	NULL
62	NULL
63	NULL
65	NULL
66	NULL
67	NULL
68	NULL
69	NULL
Zhou	NULL
,	NULL
H.	NULL
,	NULL
$	NULL
u	NULL
,	NULL
H.S	NULL
.	NULL

,	NULL
Zhang	NULL
,	NULL
X.	NULL
,	NULL
Douhan	NULL
and	NULL
Glimcher	NULL
,	NULL
L.H	NULL
.	NULL

(	NULL
1997	NULL
)	NULL
J	NULL
.	NULL

Immunol	NULL
.	NULL

,	NULL
158	NULL
,	NULL
4741-4749	NULL
.	NULL

Bontron	NULL
,	NULL
S.	NULL
,	NULL
Ucla	NULL
,	NULL
C.	NULL
,	NULL
Mach	NULL
,	NULL
B	NULL
.	NULL

and	NULL
Steimle	NULL
,	NULL
V	NULL
.	NULL

(	NULL
1997	NULL
)	NULL
Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

,	NULL
17	NULL
,	NULL
4249-4258	NULL
.	NULL

Yun	NULL
,	NULL
S.	NULL
,	NULL
Gustafsson	NULL
,	NULL
K	NULL
.	NULL

and	NULL
Fabre	NULL
,	NULL
J.W	NULL
.	NULL

(	NULL
1997	NULL
)	NULL
Int	NULL
.	NULL

Immunol	NULL
.	NULL

,	NULL
9	NULL
,	NULL
1545-1553	NULL
.	NULL

Heery	NULL
,	NULL
D.M	NULL
.	NULL

,	NULL
Kalkhoven	NULL
,	NULL
E.	NULL
,	NULL
Hoare	NULL
,	NULL
S	NULL
.	NULL

and	NULL
Parker	NULL
,	NULL
M.G	NULL
.	NULL

(	NULL
1997	NULL
)	NULL
Nature	NULL
,	NULL
387	NULL
,	NULL
733-736	NULL
.	NULL

Torchia	NULL
,	NULL
J.	NULL
,	NULL
Rose	NULL
,	NULL
D.W.	NULL
,	NULL
Inostroza	NULL
,	NULL
J.	NULL
,	NULL
Kamei	NULL
,	NULL
Y.	NULL
,	NULL
Westin	NULL
,	NULL
S.	NULL
,	NULL
Glass	NULL
,	NULL
C.K	NULL
.	NULL

and	NULL
Rosenfeld	NULL
,	NULL
M.G	NULL
.	NULL

(	NULL
1997	NULL
)	NULL
Nature	NULL
,	NULL
387	NULL
,	NULL
677-684	NULL
.	NULL

Scholl	NULL
,	NULL
T.	NULL
,	NULL
Mahanta	NULL
,	NULL
S.K	NULL
.	NULL

and	NULL
Strominger	NULL
,	NULL
J.L	NULL
.	NULL

(	NULL
1997	NULL
)	NULL
Proc	NULL
.	NULL

Natl	NULL
Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
,	NULL
94	NULL
,	NULL
6330-6334	NULL
.	NULL

Clauss	NULL
,	NULL
LM	NULL
.	NULL

,	NULL
Gravallese	NULL
,	NULL
E.M.	NULL
,	NULL
Darling	NULL
,	NULL
J.M	NULL
.	NULL

,	NULL
Shapiro	NULL
,	NULL
F.	NULL
,	NULL
Glimcher	NULL
,	NULL
M.J	NULL
.	NULL

and	NULL
Glimcher	NULL
,	NULL
L.H	NULL
.	NULL

(	NULL
1993	NULL
)	NULL
Dev	NULL
.	NULL

Dyn	NULL
.	NULL

,	NULL
197	NULL
,	NULL
146-156	NULL
.	NULL

Louis-Plence	NULL
,	NULL
P.	NULL
,	NULL
Moreno	NULL
,	NULL
C.S	NULL
.	NULL

and	NULL
Boss	NULL
,	NULL
J.M	NULL
.	NULL

(	NULL
1997	NULL
)	NULL
J	NULL
.	NULL

Immunol	NULL
.	NULL

,	NULL
159	NULL
,	NULL
3899-3909	NULL
.	NULL

Reith	NULL
,	NULL
W.	NULL
,	NULL
Siegrist	NULL
,	NULL
C.A	NULL
.	NULL

,	NULL
Durand	NULL
,	NULL
B.	NULL
,	NULL
Barras	NULL
,	NULL
E	NULL
.	NULL

and	NULL
Mach	NULL
,	NULL
B	NULL
.	NULL

(	NULL
1994	NULL
)	NULL
Proc	NULL
.	NULL

Natl	NULL
Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
,	NULL
91	NULL
,	NULL
554-558	NULL
.	NULL

Westerheide	NULL
,	NULL
$	NULL
8.D	NULL
.	NULL

,	NULL
Louis-Plence	NULL
,	NULL
P.	NULL
,	NULL
Ping	NULL
,	NULL
D.	NULL
,	NULL
He	NULL
,	NULL
X.-F.	NULL
and	NULL
Boss	NULL
,	NULL
J.M	NULL
.	NULL

(	NULL
1997	NULL
)	NULL
J	NULL
.	NULL

Immunol	NULL
.	NULL

,	NULL
158	NULL
,	NULL
4812-4821	NULL
.	NULL

Wright.K.L	NULL
.	NULL

and	NULL
Ting.J.P-Y	NULL
.	NULL

(	NULL
1992	NULL
)	NULL
Proc	NULL
.	NULL

Nail	NULL
Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
,	NULL
89	NULL
,	NULL
7601-7605	NULL
.	NULL

Kara	NULL
,	NULL
C.J	NULL
.	NULL

and	NULL
Glimcher	NULL
,	NULL
L.H	NULL
.	NULL

(	NULL
1993	NULL
)	NULL
J	NULL
.	NULL

Immunol	NULL
.	NULL

,	NULL
150	NULL
,	NULL
4934-4942	NULL
.	NULL

Chin	NULL
,	NULL
K.-C.	NULL
,	NULL
L1	NULL
,	NULL
G	NULL
.	NULL

and	NULL
Ting.J.P.-T.	NULL
(	NULL
1997	NULL
)	NULL
J	NULL
.	NULL

Immunol	NULL
.	NULL

,	NULL
159	NULL
,	NULL
2789-2794	NULL
.	NULL

Shaulian	NULL
,	NULL
E.	NULL
,	NULL
Zauberman	NULL
,	NULL
A.	NULL
,	NULL
Ginsberg	NULL
,	NULL
D	NULL
.	NULL

and	NULL
Oren	NULL
,	NULL
.M	NULL
.	NULL

(	NULL
1997	NULL
)	NULL
Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

,	NULL
12	NULL
,	NULL
5581-5592	NULL
.	NULL

Aperio	NULL
,	NULL
C.	NULL
,	NULL
Pognonec	NULL
,	NULL
P	NULL
,	NULL
Stanley	NULL
,	NULL
E.R	NULL
.	NULL

and	NULL
Boulukos	NULL
,	NULL
K.E	NULL
.	NULL

(	NULL
1996	NULL
)	NULL
Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

,	NULL
16	NULL
,	NULL
6851-6858	NULL
.	NULL

Attardi	NULL
,	NULL
L.D	NULL
.	NULL

,	NULL
Von	NULL
Seggem	NULL
,	NULL
D	NULL
.	NULL

and	NULL
Tjian	NULL
,	NULL
R	NULL
.	NULL

(	NULL
1995	NULL
)	NULL
Proc	NULL
.	NULL

Nat	NULL
!	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
,	NULL
90	NULL
,	NULL
10563-10567	NULL
.	NULL

Dever	NULL
,	NULL
LE	NULL
.	NULL

,	NULL
Glynias	NULL
,	NULL
MJ	NULL
.	NULL

and	NULL
Merrick	NULL
W.C.	NULL
,	NULL
(	NULL
1987	NULL
)	NULL
Proc	NULL
.	NULL

Natl	NULL
Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
,	NULL
84	NULL
,	NULL
1814-1818	NULL
.	NULL

Walker	NULL
,	NULL
J.E	NULL
.	NULL

,	NULL
Saraste	NULL
,	NULL
M.	NULL
,	NULL
Runswick	NULL
,	NULL
M.J.	NULL
and	NULL
Gay	NULL
,	NULL
N.J	NULL
.	NULL

(	NULL
1982	NULL
)	NULL
EMBO	NULL
J.	NULL
,	NULL
1	NULL
,	NULL
945-951	NULL
.	NULL

Chakrabartty	NULL
,	NULL
A.	NULL
,	NULL
Doig	NULL
,	NULL
A.J	NULL
.	NULL

and	NULL
Baldwin	NULL
,	NULL
R.L	NULL
.	NULL

(	NULL
1993	NULL
)	NULL
Proc	NULL
.	NULL

Natl	NULL
Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
,	NULL
90	NULL
,	NULL
11332-11336	NULL
.	NULL

Fontes	NULL
,	NULL
J.D	NULL
.	NULL

,	NULL
Jiang	NULL
,	NULL
B	NULL
.	NULL

and	NULL
Peterlin	NULL
,	NULL
B.M	NULL
.	NULL

(	NULL
1997	NULL
)	NULL
Nucleic	NULL
Acids	NULL
Res	NULL
.	NULL

,	NULL
25	NULL
,	NULL
2522-2528	NULL
.	NULL

Bontron	NULL
,	NULL
S.	NULL
,	NULL
Steimle	NULL
,	NULL
V.	NULL
,	NULL
Ucla	NULL
,	NULL
C	NULL
.	NULL

and	NULL
Mach	NULL
,	NULL
B	NULL
.	NULL

(	NULL
1997	NULL
)	NULL
Hum	NULL
.	NULL

Genet	NULL
.	NULL

,	NULL
99	NULL
,	NULL
541-546	NULL
.	NULL

